THE CHALLENGE OF PROVIDING AN EFFECTIVE, BUT TECHNICALLY COMPLEX,
VACCINE TO THE DEVELOPING WORLD.
Emilio A. Emini, Ph.D., Vaccine R&D, Wyeth Pharmaceuticals
500 Arcola Road, Collegeville, PA, 19426, U.S.A.
T: 1-484-865-6490, F: 1-484-865-6477, eminie@wyeth.com
PREVENAR® is arguably one of the most successful vaccines ever developed. It is designed to
provide protective immunity against the seven serotypes of Streptococcus pneumoniae most
commonly associated with invasive pneumococcal disease. Universal immunization of infants
with PREVENAR was introduced in the United States in 2000. Since then, the U.S. has witnessed
a greater than 98% decline in disease caused by the seven pneumococcal serotypes in the
vaccine and, as a result of herd immunity, a greater than 50% decline of disease in adults.
Currently the vaccine is registered in over 80 countries and, in a number of these, is included in
the national immunization program. Yet, in spite of the vaccine’s success, pneumococal disease
remains the largest cause of vaccine-preventable death of children in the developing world. An
imperative exists to bring PREVENAR to developing world countries. However, a significant
challenge facing such an effort is the vaccine’s complexity. It is composed of seven purified
polysaccharides, each covalently conjugated onto a carrier protein, and specifically combined into
a single formulation. The complexity is compounded for the second-generation vaccine, currently
in phase 3 development, which is designed to expand serotype coverage to include an additional
six serotypes. The latter are particularly important for protection against pneumococcal disease in
the developing world. The production and manufacturing control of the vaccines is complex and
involves multiple worldwide manufacturing sites. These represent potentially substantial
impediments facing the provision of the hundreds of millions of vaccine doses that are needed.
Nonetheless, given the vaccine’s effectiveness and medical importance, the challenges must be
overcome. The present discussion will specifically define the challenges and will provide a
context for evaluating potential solutions.
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HUMAN MONOCLONAL ANTIBODIES AND ANALYTIC VACCINOLOGY
Antonio Lanzavecchia, Institute for Research in Biomedicine
Via Vincenzo Vela 6, Bellinzona, 6500, Switzerland
T: +41 (0)91 820 0310, F: +41 (0)91 820 0312, lanzavecchia@irb.unisi.ch
Following appropriate priming by infection or vaccination, memory B cells and serum antibody
levels are sustained for a lifetime conferring immediate protection upon secondary encounter with
the pathogen. I will first discuss the differential requirements for activation of human naïve and
memory B cells and describe two methods that can be used to interrogate the human memory B
cell repertoire. The first is based on limiting dilution analysis of polyclonally stimulated
mononuclear cells. Using this method, we measured the frequency and fine specificity of memory
B cells in serial samples under steady state conditions and after vaccination. The second method
is based on the efficient immortalization and cloning of memory B cells. Using this method we
have been able to isolate from the human memory repertoire several potent and broadly
neutralizing monoclonal antibodies against viruses such as SARS, Dengue, H5N1, HCMV and
HIV-1. I will discuss how such antibodies can be used not only to provide immediate protection,
but also as probes for epitope discovery and vaccine design.
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UTILIZING INFLUENZA VACCINATION TO RAPIDLY CLONE HIGH AFFINITY HUMAN
MONOCLONAL ANTIBODIES AND TO TEST THE CONCEPT OF ORIGINAL ANTIGENIC SIN
Jens Wrammert, Emory Vaccine Center; Emory University
1510 Clifton Rd., Atlanta, GA, 30322, USA
T: 404-371-1677, F: 404-727-3722, wrammert@microbio.emory.edu
Rafi Ahmed, Emory Vaccine Center; Emory University
Donald Capra, Oklahoma Medical Research Foundation
Patrick Wilson, Oklahoma Medical Research Foundation
Pre-existing neutralizing antibody provides a first line of defence against pathogens. For influenza
virus, annual vaccinations are given to maintain protective levels of antibody against the currently
circulating strains. We show that a booster vaccination induced a rapid and robust influenza
specific IgG antibody-secreting cell (ASC) response that accounted for up to 6% of peripheral
blood B cells at the peak. Importantly, as much as 80% of purified ASCs were influenza specific
at the peak of the response. This ASC response was characterized by a highly restricted B-cell
receptor (BCR) repertoire that in some donors was dominated by only a few B-cell clones. This
pauciclonal response, however, showed extensive intraclonal diversification from accumulated
somatic mutations. We used the immunoglobulin variable regions isolated from sorted single
ASCs at the peak of the response to produce over 50 human monoclonal antibodies (mAbs) that
bound to the three influenza vaccine strains with high affinity. This strategy demonstrates that we
can generate multiple high affinity mAbs from humans within a month after vaccination. The panel
of influenza-virus-specific human mAbs allowed us to address the issue of original antigenic sin
(OAS): the phenomenon where the induced antibody shows higher affinity to a previously
encountered influenza virus strain compared with the virus strain present in the vaccine.
However, we found that most of the influenza-virus-specific mAbs showed the highest affinity for
the current vaccine strain. Thus, OAS does not seem to be a common occurrence in normal,
healthy adults receiving influenza vaccination.
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ANTI-VIRAL IMMUNE RESPONSES IN LYMPH NODES
Ulrich H. von Andrian, Harvard Medical School
77 Ave. Louis Pasteur, Boston, MA, 02115, USA
T: 617-432-6828, F: 617-432-6829, uva@hms.harvard.edu
Cell migration and coordinated cell-cell interactions are hallmarks features of the immune
response to antigen challenge. Recent advances in real-time in vivo imaging technology have
added a new dimension to our efforts to understand the dynamics and complex interplay of the
key cellular players in the steady state and during ongoing immune responses. In particular,
multiphoton intravital microscopy (MP-IVM) allows prolonged three-dimensional observations of
highly dynamic events that occur hundreds of micrometers below the surface of solid tissues in
living animals. The capacity to visualize the cellular dynamics in skin-draining lymph nodes is of
particular importance because these organs are the primary sites of immune recognition of
transcutaneously administered antigens, including vaccines.
We have recently developed a MP-IVM model in mouse popliteal lymph nodes, which has
allowed us to analyze, in real time, how T and B cells respond to cognate antigens derived from
the skin and subcutaneous tissue. Specifically, we have examined how follicular lymph node B
cells become first exposed to viral particles after intradermal injection. Within minutes after
injection, intact viral particles accumulated on a discrete population of CD169+ macrophages that
populated the floor of the subcapsular sinus (SCS). Using MP-IVM, immunohistochemistry and
electron microscopy, we found that these cells were critical in presenting antigens to virusspecific B cells in the underlying follicles. Moreover, upon selective depletion of lymph noderesident macrophages by subcutaneous injection of clodronate liposomes, the downstream lymph
nodes were no longer able to prevent the systemic spread of lymph-borne virus, indicating that
the SCS macrophages play a dual role as critical antigen-presenting cells for follicular B cells and
as innate “flypaper” for skin-derived lymph-borne pathogens.
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USING VACCINES TO REVEAL HUMAN IMMUNE SYSTEM FUNCTION AND THE
PATHOGENESIS OF ZOONOTIC DISEASES
Mark Feinberg, Merck & Co., Inc.
(Abstract not received in time for printing)
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FIRST CLINICAL EFFICACY TRIAL OF AN ADENOVIRUS TYPE 5-BASED HIV-1 VACCINE:
THE STEP STUDY
Danilo Casimiro, Merck & Company
770 Sumenytown Pike, West Point, Pennsylvania, 19486, USA
T: 1 215 652 3129, F: 1 215 652 9130, danilo_casimiro@merck.com
Michael Robertson, Devan Mehrotra, John Shiver, Merck & Company, USA
Susan Buchbinder, San Francisco Department of Public Health, USA
Dan Fitzgerald, GHESKIO, Haiti
Ann Duerr, Juliana McElarth, Larry Corey, HIV Vaccine Trials Network, USA
Background: Recent activities in HIV-1 vaccine R&D have focused on vaccine candidates
capable of inducing HIV-specific T cell immune responses. Such vaccines have shown partial
success in some animal models, but this concept has not been previously tested in humans.
Methods: A collaborative study between Merck, the HIV Vaccine Trials Network, and US National
Institute of Allergy and Infectious Diseases was initiated in 2004. This phase II, randomized,
multi-center, double-blind, placebo-controlled test-of-concept study enrolled 3000 HIV
seronegative volunteers at high risk of acquiring HIV in regions of the world where clade B
predominates. Volunteers were randomized (1:1) to receive 3 injections (Day 1, Week 4 and
Week 26) of either the MRKAd5 HIV-1 gag/pol/nef vaccine (a replication defective Ad5 vector) or
placebo. Randomization was pre-stratified by gender, baseline Ad5 titer, and study site.
Volunteers were tested at 6–month intervals for HIV acquisition. In volunteers who became HIV
infected, plasma HIV viral load and CD4 cell counts were measured at multiple time points postdiagnosis. Serum, plasma and PBMC were collected at multiple time points in all volunteers for
laboratory analyses.
Results: In September 2007 an independent DSMB reviewed data from a planned interim
analysis in volunteers with low (<200) baseline Ad5 neutralizing antibody titers (the primary
analysis population). Using a modified 'intent-to-treat' approach, in this stratum, there were 24
infections among the 741 vaccinees compared to 21 infections among the 762 placebo recipients.
Among those who became HIV infected, the geometric mean plasma HIV RNA level was ~40,000
copies/mL in the vaccine group compared to ~26,000 copies/mL in the placebo group. Lack of
efficacy did not appear to be explained by lack of vaccine-induced immune responses in
vaccinees. Post-hoc analyses demonstrated that the trend towards more infections in the vaccine
group was more pronounced in volunteers with high (>200) baseline Ad5 titers (21 infections in
392 vaccinees vs. 9 in 386 placebo recipients).
Conclusions: There was no evidence that vaccination prevented infection or lowered viral load
setpoint; in fact, there were more infections in the vaccine group. Investigations are under way to
understand if these results are explained by immune responses induced by the vaccine, by
differences in the study populations or, since the numbers are relatively small, simply due to
chance. Because of the implications for the development of other CMI based vaccines, it will be
important to understand the potential mechanisms underlying these results.
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QUALITY ISSUES: THE GOOD-ENOUGH VACCINE
Philip Minor, NIBSC
Blanche Lane, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom
T: 44 (0) 1707 641000, F: 44 (0) 1707 641366, pminor@nibsc.ac.uk
pminor@nibsc.ac.uk,
Most vaccines cannot be treated as well characterised chemical entities but they are among the
most successful medical interventions. Confidence in their effect is based on properties that may
or may not be correctly identified as markers of clinical safety or efficacy but which are related to
the consistency of production. Vaccines against Human Papilloma Virus and poliomyelitis will be
used as examples.
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NEW METHODS FOR DETECTING ADVENTITIOUS AGENTS
David Onions, BioReliance
301 Avenida do Mar, vale do Lobo, Almancil Algarve, 8235-024, Portugal
T: 351 289 358 667, F: 999 999 9999, david.onions@bioreliance.com
Jeri Ann Boose, Martin Wisher, Alison Armstrong, Clare Blue, BioReliance
Ruth Jarrett, University of Glasgow
Two factors have driven new approaches to adventitious agent testing in vaccine production; the
need for more rapid assays to test bulk product and the requirement to thoroughly exclude latent
adventitious agents in new cell substrates.
European and US regulatory authorities have opened the door to PCR based testing methods to
detect mycoplasma contamination, facilitating rapid screening. However, direct PCR methods
suffer from two disadvantages, often only a small volume from the fermenter is tested and
secondly the assays do not distinguish between viable organisms and contaminating mollicute
DNA that can be introduced from animal and animal free reagents like serum and plant
hydrolysates respectively. We have developed a hybrid culture-PCR method “HyMy” that
provides the advantages of culture while shortening the assay period from 28 days to 14 days. In
the next phase we will introduce hybrid culture and molecular detection systems for both bacteria
and viruses.
One of the tools we are investigating for the rapid detection of viruses are cells engineered with
beta-lactamase constructs linked to interferon response elements. Exposure of the indicator cells
to interferon from virus infected cells leads to conditional expression of beta-lactamase. This
enzyme will cleave appropriate FRET substrates leading to a blue fluorescence within the cells at
an early stage in the infection cycle.
The recent acceptance of tumorogenic cells, like MDCK cells, as substrates for the production of
prophylactic vaccines has been a major change in the industry. It has prompted an
unprecedented level of investigation of the cells for adventitious agents, particular for viruses that
might be oncogenic or latent. While specific viruses can be excluded by QPCR analysis, the
potential for unknown agents remains. We have developed degenerate PCR systems for the
detection of all known polyomaviruses and herpesviruses and demonstrated the utility of this
approach through the identification of new herpesviruses in pigs and primates. We are now
investigating the use of oligonucleotide arrays coupled to random PCR reactions to detect a wider
range of potential contaminants in these new cell substrates.
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TOWARDS A THERAPEUTIC HEPATITIS C VACCINE – A PRECLINICAL AND CLINICAL
LEARNING CURVE
Alexander von Gabain, Intercell AG
Campus Vienna Biocenter 6, Vienna, Vienna, A-1030, Austria
T: +43120620102, F: +43120620801, agabain@intercell.com
Novel approaches for treatment of chronic HCV infection are urgently needed. To this end, we
have comprehensively identified disease relevant viral T-cell epitopes derived from therapy
responders and spontaneous resolvers. Based on this analysis, we designed a prototypic peptide
vaccine, IC41 that is containing CD8 and CD4 T-cell epitopes and poly-L-arginine as adjuvant.
Correlation of immune and RNA response showed that the single parameter correlating best with
RNA decline was induction of CD8 CTLs, above a critical threshold. Responses were dominated
by T-cells directed against the viral NS3 protein, and in one patient a viral amino acid exchange
of a vaccine epitope resulted in reduced epitope recognition that emerged prior RNA rebound.
The observed mutational T-cell escape corroborates a causal relationship of T cell induction and
HCV RNA decline. Further pre-clinical (HLA transgenic mice) and clinical trials (healthy
volunteers) identified an optimized application schedule of our vaccine with significant stronger
CD8 responses and broader simultaneous responses against CTL epitopes. Based on this study
a novel trial in chronic HCV genotype 1 patients naïve to ST was initiated. The data obtained
shows that the primary endpoint set for this study, namely a statistically significant sustained
HCV-RNA decline, has been met. In the second week after the final vaccination, a 40 % reduction
of viral load was observed in comparison to the baseline prior to vaccination. The therapeutic
effect of the vaccine on the viral load is small, but found to be significant when data was
submitted for rigorous statistical analysis (p=0.0010). The results are especially significant in the
light of the observation that viral load reduction is increasing with the number of vaccinations. The
study included patients with various levels of viral load. In the subset of patients (N=25 with high
viral load (> 2 million copies/ml) before treatment, a statistically significant (p=0.0001) average
decline of 60 % (0.4 log) was achieved. Thus, it seems that the therapeutic effect is more
pronounced when the patients’ immune system is unable to keep the viral load under control.
With this data, we will move forward with a second generation vaccine that includes further T-cell
epitopes and where poly-L-arginine will be replaced by IC31TM , a novel adjuvant that has shown
to induce in preclinical and clinical settings a sustained and superior level of pivotal T-cells. The
previous data and the design of the novel vaccine will be discussed in my presentation.
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DELIVERY DEVICES AND APPROACHES FOR PRE-CLINICAL AND CLINICAL HIV
IMMUNIZATION
Britta Wahren, Karolinska Institute
Department of Microbiology, Tumor and Cell Biology (MTC), Stockholm, SE-171 77, Sweden
T: 46 0 8457 2630, F: 46 0 833 7272, britta.wahren@smi.ki.se
Preclinical delivery methods. Vaccine delivery methods are essential in humans but may not be
identical to those effective in animals. DNA vaccines were used to investigate different forms of
deliveries (1-8). In mice and macaques skin delivery (id by biojector, syrijet or gold beads) and
mucosal delivery (nasal, oral, rectal) appear more potent than intramuscular or subcutaneous
administration. In a transgenic murine model we have shown complete protection after mucosal
or dermal gene vaccination and HIV challenge. Plasmid DNA encoding HIV antigens was
delivered intradermally by electroporation. This resulted in a very rapid induction of potent
immune responses.
Clinical studies. Both mucosal (oral by syrijet) and intradermal (by biojector) administration of
genetic vaccines have shown capacity to induce potent immunity, indicating that it is possible to
significantly reduce the amount of DNA needed for intramuscular immunization. The use of an
HIV DNA vaccine prime followed by modified vaccinia Ankara carrying multiple HIV genes gave
very high antigen-specific and broad response rates in a recent phase 1 clinical trial (5-6). In an
ongoing study of infected individuals, DNA is delivered to abrased skin, aided by transfecting
agent and occlusive dressing (8). The use of the skin delivery pathway may help both systemic
and mucosal immunity, by inducing a persistent systemic immunity. The broad representation of
different subtype genes of HIV combined with the widely distributed skin delivery may contribute
to potent immunogenicity in humans.
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FLAVIVIRUS CAPSID DELETION MUTANTS AS A NEW VACCINE APPROACH
Christian W. Mandl, Medical University of Vienna, Institute of Virology, Vienna, Austria
Flaviviruses are a group of arthropod-transmitted pathogens of major and ever-increasing,
medical importance. Among the most relevant human pathogens are yellow fever virus (YFV),
Japanese encephalitis virus (JEV), West Nile virus (WNV), the dengue viruses (DV), and tickborne encephalitis virus (TBEV). In the absence of any available specific antiviral drugs, disease
prevention by vaccination represents the most important and effective measurement to combat
flavivirus diseases.
In the past, both live attenuated vaccines (against YFV and JEV in China) and inactivated whole
virus vaccines (JEV and TBEV) have proven very successful to reduce disease burden.
Nevertheless, new vaccination strategies are in big demand to meet the many challenges
imposed by flavivirus infections. The rapid invasion of North America by West Nile virus illustrates
the potential of these pathogens to establish themselves in new geographical regions and to
infect a multitude of host organisms. The geographical expansion of endemic areas,
socioeconomic changes in, and the rising travel activities to such areas steadily increases the
number of people at risk of infection. A particular problem for vaccine development is imposed by
the difficult immunopathogenesis that is seen with successive dengue virus infections, which has
hampered attempts to develop dengue vaccines.
We have explored the possibility of using genetically engineered flavivirus mutants with specific
deletions in the capsid protein gene as a new vaccine approach. Remarkably, replication
competent viral strains can be obtained which lack up to one third of the amino acid sequence of
this structural protein. Due to this modification, an increased proportion of non-infectious, but
highly immunogenic subviral particles are produced. This approach has been shown for TBEV
and WNV to generate apathogenic vaccine strains and is likely applicable also to other
flaviviruses. In the mouse model, capsid deletion mutants achieved a higher attenuation index
(ratio of 50%-lethal dose to 50%-protective dose) than observed for any other attenuating
principle tested in the same system and induced a solid, protective immune response. The
introduction of even larger deletion mutations into the capsid gene yielded mutants which could
not be propagated in cell culture, but represent self-replicating RNAs which can undergo major
steps of the viral life cycle in vivo. Significantly, these RNA replicons produce ample amounts of
highly immunogenic subviral particles. We have explored in the mouse model the application of
such self-replicating RNA as a new type of nucleic acid vaccine. This approach combines
features of classical live vaccines, such as the in vivo production of RNA replication intermediates
and all relevant viral antigens, with the advantages of a nucleic acid vaccine. The absence of viral
spread in the host in this replicon approach is a relevant safety feature. Capsid deletion mutants
hold promise to overcome the particular challenges to vaccine development imposed by dengue
viruses.
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VIRAL VECTORS – COUPLING INNATE SIGNALS TO ANTIGEN EXPRESSION AND
PRESENTATION
Peter Liljeström, Karolinska Institutet
PO Box 280, Stockholm, 171 77, Sweden
T: +4684572550, F: +468310848, Peter.Liljestrom@ki.se
Several viral vectors and DNA vaccines are being developed as vehicles for recombinant
vaccines and many of them have already entered clinical trials. Results from both preclinical
studies and clinical trials have indicated that vectors expressing similar or identical inserts
generate qualitatively different immune responses. These findings probably bear on the fact the
different vectors target different innate immune pathways thus resulting dissimilar acquired
responses. Furthermore, it is becoming evident that e.g. measurements of only quantitative T cell
responses do not necessarily correlate to levels of protection for a certain vaccine. For example,
in the P1A mouse tumor model animals immunized with a recombinant adenovirus (Ad5) vector
expressing the P1A antigen generated significantly higher T cell responses than did animals that
had been immunized with a recombinant alphavirus vector (Semliki Forest virus – SFV) based
vaccine expressing exactly the same P1A antigen. However, upon tumor challenge the animals
that had been immunized with the alphavirus vaccine showed significantly better protection than
did the corresponding Ad5 immunized animals. Analysis of the SFV induced memory T cells
indicated that their capacity to expand upon recall was much greater than the Ad5 induced T
cells. As also heterologous prime-boost regimens using at least two kinds of vectors are being
contemplated careful analysis of the qualities of different vectors need to be assessed separately
and in combination. These aspects will be discussed in light of several examples from preclinical
and clinical trials.
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VEEV REPLICON-BASED VACCINES USED IN HETEROLOGOUS PRIME BOOST
STRATEGIES INDUCE LIFELONG PROTECTION FROM PROSTATE CANCER AND
THERAPY OF CERVICAL CANCER IN MICE AND ROBUST CELL-MEDIATED IMMUNITY IN
RHESUS MACAQUES
W. Martin Kast, Norris Comprehensive Cancer Center, University of Southern California
1450 Biggy Street, Los Angeles, CA, 90033, USA
T: x1 323 442 3870, F: x1 323 442 7760, mkast@usc.edu
Therapeutic HPV vaccines, based upon platforms of Venezuelan equine encephalitis virus
replicon particles (VRP) and attenuated recombinant Vesicular Stomatitis Virus (VSV) vectors,
both expressing mutated E7-E6 fusion proteins from the high-risk HPV16 and 18 genotypes, were
tested in various homologous or heterologous prime-boost regimens in mice and in Rhesus
macaques to assess levels of immunogenicity and anti-tumor immunity. Anti-tumor immunity was
assessed by prophylactic and therapeutic vaccination with the HPV16 E7-E6 coding vectors in
mice against HPV16-transformed tumors. Full protection from tumor challenge was observed
after immunization with all three VRP/VRP, VSV/VSV, and VRP/VSV regimens. Therapeutic
immunization of tumor-bearing mice showed 75% rejection of tumors in mice treated with
VRP/VRP or VSV/VSV regimens and 100% rejection in mice treated with VRP/VSV combination
strategies. Rhesus macaques vaccinated intramuscularly with three doses of VRP four weeks
apart and boosted once with VSV showed very robust and sustained antigen-specific IFN gamma
and IL-2 ELISPOT responses against HPV E6 and E7 peptides. In contrast to mice, only modest
responses were detected after three doses of VRP alone or two doses of VSV alone in the
macaques. In a separate TRAMP mouse prostate cancer model VRP in combination with DNA
based vaccines both coding for the prostate cancer associated antigens PSCA or STEAP were
able to induce lifelong protection against prostate cancer development when the male mice were
vaccinated at an age of 8 weeks, which is the stage at which they have developed prostate
intraepithelial neoplasia. All control vaccinated mice had succumbed of prostate cancer within a
year but of the DNA prime VRP boost immunized mice 90% were alive and apparently healthy at
month 12 and 65% at month 18. In conclusion, these strong in vivo anti-tumor responses both in
cervical cancer and prostate cancer models and the unprecedented high cellular immune
responses in non-human primates after heterologous VRP prime and VSV boost or in mice DNA
prime and VRP boost provide strong justification for further development of the VRP platform for
therapeutic anti-tumor vaccines delivery.
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EFFICIENT AND ECONOMICAL INFLUENZA VACCINES INCORPORATING A TOLL-LIKE
RECEPTOR LIGAND
Alan R. Shaw, VaxInnate Corporation
3 Cedarbrook Drive, Cranbury, New Jersey, 08512, USA
T: (1) 609-860-2262, F: (1) 609-860-2290, alan.shaw@vaxinnate.com
James Huleatt, sanofi-pasteur
Ge Liu, Scott Umlauf, Langzhou Song, Andrea Jacobs, William McDonald, Bruce Weaver, Doug
Krouse, VaxInnate
Robert Evans, Merck Research Laboratories
David Jackson, Jeff Powell, David Taylor, and Lynda Tussey, VaxInnate
Pathogens display and produce a variety of molecules that are unique and not found in higher
order animals. Examples include lipopolysaccharide, unmethylated CpG DNA, double-stranded
RNA, and flagellins. Collectively, these motifs are called Pathogen-Associated Molecular
Patterns, or PAMPs. Nature has evolved a system of receptors that recognize the various classes
of PAMPs, and one major category of these receptors is known as the Toll-Like Receptors or
TLRs. TLRs are expressed on the surface of, or on membrane-bounded vesicles inside, cells
capable of processing and presenting antigens to T-cells. Uptake of a pathogen by an antigenpresenting cell via a TLR results in highly efficient processing and presentation of the antigens of
the pathogen. Our laboratory has adapted this TLR-mediated antigen uptake process for the
design of vaccines against influenza. We fuse the genetic sequence for flagellin, the ligand for
TLR5, in-frame with the sequence for influenza antigens. We have two independent, but
complementary approaches to influenza vaccination. The first vaccine targets the ectodomain of
the highly conserved ion channel protein, M2e. M2e is small (24aa), present in low copy number,
and poorly immunogenic in the context of natural infection. A vaccine comprising flagellin fused to
four copies of M2e provides complete protection against death and severe disease in mice
challenged with an LD90 dose of live virus. This vaccine has been shown to be safe and highly
immunogenic in humans. The second vaccine, directed at the globular head moiety of
hemagglutinin, elicits potent neutralizing antibody responses and provides complete protection
against disease and death in mice challenged with an LD90 dose of live virus. Both vaccines are
produced by standard rDNA methods in E. coli at very high yield and low cost. Production levels,
antigen per volume of starting fluids, are approximately three logs higher than the current eggbased system, making the distribution of both pandemic and seasonal vaccines world wide a
workable possibility.
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FLUBLOK, A HIGH DOSE RECOMBINANT INFLUENZA VACCINE
Manon MJ Cox, Protein Sciences Corporation
1000 Research Parkway, Meriden, CT, 06450, USA
T: 203 686 0800, F: 203 686 0268, manon.cox@proteinsciences.com
Influenza vaccine effectiveness of inactivated vaccines needs to be improved particularly when
vaccine strains and circulating strains are poorly matched not only for those at high risk. For
example, the 2007-2008 inactivated influenza vaccine provided only 44% vaccine effectiveness
according to a recent CDC Morbidity and Mortality Weekly Report (April 18, 2008, Vol 57, No 15).
Four simple ways to improve vaccine performance are: 1) Increase the number of doses, 2)
Increase the hemagglutinin content; 3) Use an adjuvant or 4) Vary the type of preparation (whole
virus vaccine, subvirion versus subunit).
A recombinant HA vaccine produced in cell culture using the baculovirus vectors system provides
an attractive alternative to the current egg-based influenza vaccine (TIV) manufacturing process
and presents the possibility for safe and expeditious vaccine production. The high purity of the
antigen enables administration at higher doses without a significant increase in side-effects in
human subjects.
The HA genes from the annual World Health Organization recommended strains are cloned,
expressed and purified using a general purification process. An overview of the expression
technology used to make the annual adjustments will be provided. The insect cell - baculovirus
production technology is a modern solution for rapid viral or parasitic antigen production and that
this technology is particularly suitable for influenza where annual adjustment of the vaccine is
required.
The safety, immunogenicity and efficacy results from four recent clinical studies conducted in
different populations (ages 18 - 49; 49- 64 and 65 and older) will be presented. The highly purified
protein vaccine, administered at three times higher antigen content than TIV is well tolerated and
results in stronger immunogenicity, a long lasting immune response and provides cross protection
against drift influenza viruses.
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CHALLENGES AND SOLUTIONS FOR THE NEXT GENERATION OF VACCINES:
DEVELOPMENT OF CELL CULTURE-BASED LIVE ATTENUATED INFLUENZA VACCINE
Jonathan Liu, MedImmune Vaccines
3055 Patrick Henry Dr, Santa Clara, CA, 95054, USA
T: 1-650-603-2576, F: 1-650-603-3576, liuj@medimmune.com
Luis Maranga, MedImmune Vaccines
Sachin Mani, MedImmune Vaccines
Richard Schwartz, MedImmune Vaccines
To rapidly meet the public demand for influenza vaccines in the event of a pandemic influenza
outbreak and with the support of a $170 million award by the US federal government,
MedImmune has intensified its R&D efforts to replace eggs as the production substrate with cellbased manufacturing for its commercial flu vaccine, FluMist®. The cell substrate under
development is an MDCK cell line developed at MedImmune. Vaccine viruses produced from
these cells maintain the characteristic phenotypes of FluMist® including cold-adaptation,
temperature sensitivity and attenuation in a ferret animal model. Here we report our progress in
characterization of the host cells and productivity improvement. In order to maximize the
productivity of the cells used for vaccine manufacturing, we screened over 2500 cell clones that
originated from an ATCC MDCK cell bank, optimized the serum-free cell growth conditions for a
dozen selected cell clones and finally produced a single master cell bank. We conducted
extensive cell bank testing that consists of a panel of 32 product specification tests, 20 cell line
characterization assays and 8 tumorigenicity and oncogenicity tests. Using this cloned MDCK cell
line we have developed an influenza vaccine production platform process that is adaptable to
various cell culture vessels. This production platform has been used to efficiently produce coldadapted vaccine strains in both conventional stir tank bioreactors and disposable bioreactors
(Single Use Bioreactors). We have produced cold-adapted influenza viruses up to 8.9 log10
fluorescent focus units per milliliter of harvest fluid and have shown that the platform process is
applicable to the production of a broad range of currently circulating cold-adapted seasonal
vaccine strains and several cold-adapted prototypic pandemic influenza viruses (H5, H7 and H9).
We will share our experience and scientific approaches to address regulatory concerns about
MDKC cell characterization, including tumorigenicity and oncogenicity, and our methods which
have increased virus productivity by more than 300-fold.

Monday, June 2

Session 3

TOWARD THE DEVELOPMENT OF A SARS VACCINE
Jeffrey Ulmer, Novartis Vaccines and Diagnostics
4560 Horton Street, M/S 4.3, Emeryville, CA, 94608, US
T: 510-923-5140, F: 510-923-5402, jeffrey.ulmer@novartis.com
The pandemic potential and pathogenicity of SARS coronavirus (SARS-CoV), as well as the
absence of effective licensed drugs, highlights the need to develop an effective SARS vaccine.
Preliminary data have indicated that a human monoclonal antibody directed toward the spike
envelope glycoprotein of SARS-CoV can neutralize virus in vitro and provide protection from live
virus challenge in animal models. Two established vaccine technologies were evaluated for their
ability to elicit protective neutralizing antibodies. First, SARS-CoV was grown in cell culture,
isolated and inactivated by beta propiolactone treatment. This killed vaccine preparation induced
neutralizing antibodies in mice, rabbits and ferrets, and conferred protection in ferrets against live
SARS CoV challenge. Second, two forms of recombinant spike glycoprotein were produced in
CHO cells and purified to near homogeneity. A full-length form was expressed as a trimer on the
cell surface, and a truncated form was expressed as a monomer and secreted from the cells.
Both recombinant proteins were recognized by the SARS-CoV neutralizing monoclonal antibody,
suggesting that important neutralization epitopes were preserved and exposed in the proteins.
Moreover, when formulated with the MF59 adjuvant, both proteins were able to induce
neutralizing antibodies in mice, rabbits and ferrets. However, the truncated form of the spike
glycoprotein was selected for further development, based on better productivity in CHO cells and
superior immunogenicity in animal models. In efficacy studies in ferrets, the recombinant subunit
truncated spike glycoprotein plus MF59 was protective against live SARS CoV challenge. In
collaboration with the NIH, the subunit vaccine is progressing toward a phase I clinical trial.
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ANALYTICAL AND MANUFACTURING CHALLENGES IN PREPARATION OF BACTERIAL
POLYSACCHARIDE CONJUGATES
Carl E Frasch, Frasch Biologics Consulting
PO Box 986, Martinsburg, West Virginia, 25402, USA
T: 1 304 263 9611, F: 1 304 263 9611, cfrasch1@juno.com
There are now highly effective conjugate vaccines against several invasive bacterial diseases of
children including those caused by Haemophilus influenzae, pneumococci and meningococci.
The commonality is that protective immunity to these diseases is directed against capsular
polysaccharides (PS). However, PSs must be covalently attached to a protein to render them
sufficiently immunogenic in young children.
To produce a conjugate vaccine, the purified PS must first be chemically modified to generate
reactive groups that can be covalently linked to the carrier protein. Prior to activation and
conjugation, generation of size reduced PS can facilitate conjugate purification, because it
facilitates later removal of unconjugated PS. There are two commonly used methods for PS
activation; periodate oxidation between adjacent carbons carrying hydroxyl groups, and
cyanylation of hydroxyls. A serous potential problem with periodate activation is induction of
conformational changes in the PS by opening of sugar ring structures.
There are a number of quality control tests that are common to most PS-protein conjugates. The
purity of the PS and carrier protein must be assured. Low molecular weight impurities in the
protein may result in inefficient conjugation. The Ps should be of known molecular size
distribution before and activation. Two critical measures after conjugate purification are the PS to
protein ratio and the percent non-conjugated saccharide (free saccharide). The latter two
measures may be considered to constitute the potency test.
From a production standpoint, yield and conjugate stability are critical considerations. Typically,
less than 20% of the activated PS becomes conjugated. Conjugate yield can be improved using
some newer conjugation methods, whereby highly reactive groups are generated on both the PS
and carrier protein. Using this approach yields can approximate 50%. Stability of the bulk and
formulated conjugate must be followed. The two major measures used to follow stability are
changes in molecular size and percent free (unbound) PS. Animal potency tests have proven to
be insensitive to changes in conjugate potency during storage. Some manufacturing processes
can yield relatively unstable conjugates.
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DEVELOPMENT OF VALIDATED ASSAYS FOR MEASURING THE HUMAN ANTIBODY
RESPONSE TO POLYSACCHARIDE CONJUGATE VACCINES
Helena Käyhty, National Public Health Institute
Mannerheimintie 166, Helsinki, 00300, Finland
T: +358 9 47441, F: +358 9 47448599, helena.kayhty@ktl.fi
At present conjugate vaccines (CV) against H. influenzae type b (Hib), N. meningitis (Men)
groups A, C W135 and Y, and 7 serotypes of S. pneumoniae (Pnc) are available. The methods
used in the evaluation of the CVs measure concentration, avidity and functional activity of antipolysaccharide (PS) antibodies.
Serum bactericidal activity (SBA) has been accepted as the method of choice for evaluating the
efficacy of MenCV. The basis for this decision was the study of Goldschneider et al in 1960’s,
which showed correlation of SBA titer (using human complement, hSBA) of lower than 4 and
acquisition of meningococcal infection in army recruits. Later, the correlate was re-evaluated after
the introduction of group C MenCV in the UK by using baby rabbit complement (rSBA); a titer of 8
or higher was associated with short term protection. Additional indicators include demonstration
of 4-fold or greater rise in SBA titer and a titer of 4 or greater by hSBA. Antibody concentration
measured by EIA standardized and validated so that it correlates with the SBA is a useful adjunct.
For evaluation of long-term protection, avidity assays for demonstration of immunological memory
have been used. The reagents and references for meningococcal assays are available from
NIBSC, Potters Bar, England.
The first HibCVs were licensed based on their efficacy in phase III trials. After that non-inferior
immune response as compared to a licensed product has been accepted as a criterion for
licensure. During the first trials with plain PS vaccine radio immunoassay (RIA) was used, and the
antibody concentrations of 0.15 and 1.00 μg/ml were introduced as threshold concentrations for
short and long-term protection, respectively. Presently EIA correlating with RIA has been used for
measuring responses to CVs. In the 1980’s and 1990’s extensive interlaboratory comparisons
and standardization of RABA and EIA took place, and at present the QC samples, reference
serum and antigens are available from NIBSC and/or US FDA. No internationally standardized
assays for measuring avidity and function of antibodies are available.
For evaluation of PncCVs standardised and validated EIA should be used. The recent
developments in EIAs have included the neutralization of unspecific antibodies by using cell wall
(CWPS) and type 22F polysaccharide. In a WHO Workshop held in 2000 a well-characterized
EIA protocol was chosen as a reference or benchmark assay. The sera for the calibration of EIA
are available from the WHO Pneumococcal Reference Laboratory at Institute of Child Health,
London, the UK, reference serum from US FDA and the antigens from ATCC (PS) and SSI,
Denmark (CWPS). Interlaboratory standardization of an assay measuring opsonophagocytic
activity (OPA) of antibodies is ongoing.

Tuesday, June 3

Session 4

THE HUMAN IMMUNE RESPONSE TO POLYSACCHARIDES AND CONJUGATES
David Goldblatt, Institute of Child Health, UCL
30 Guilford Street, London, Middx, WC1N 1EH, UK
T: +44 207 813 8491, F: +44 207 813 8494, d.goldblatt@ich.ucl.ac.uk
Encapsulated gram positive and gram negative bacteria colonise the human nasopharynx and
are important causes of human disease.Haemophilus influenzae type b (Hib), Neisseria
meningitidis Group C and Streptococcus pneumoniae are examples of such pathogens
responsible for meningitis, pneumonia and other syndromes. Antibodies to the capsular
polysaccharides surrounding these pathogens are known to mediate protection in humans, yet
vaccines derived from purified capsule (which behaves as a T cell independent antigen) are not
immunogenic or protective in those most at risk ie the young and the elderly. Conjugate vaccines,
where the polysaccharide is conjugated to a protein carrier, have revolutionised this field by
rendering the sugar moiety immunogenic even in the very young. The T cell dependent nature of
the immune response to the conjugate is also associated with the phenomenon of “boostablity”
rendering the polysaccharide immunogenic in primed infants who would otherwise not respond.
Widespread use of such vaccines has demonstrated their high impact on reducing infectious
disease thanks to both direct and indirect effectiveness.
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THE IMPACT OF POLYSACCHARIDE CONJUGATE VACCINES
George Siber, Consultant, USA
(Abstract not received in time for printing)
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REGULATORY ISSUES ASSOCIATED WITH THE DEVELOPMENT OF A COMPREHENSIVE
MENINGOCOCCAL VACCINE
Ian M Feavers, Division of Bacteriology, NIBSC
Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom
T: +44 1707 641000, F: +44 1707 641054, ifeavers@nibsc.ac.uk
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia throughout the
world. Polysaccharide conjugates, arguably the most important vaccine development of the late
20th century, have provided a partial solution to the prevention of meningococcal disease.
However, there is no vaccine that will offer protection against meningococci expressing a group B
polysaccharide capsule. The poor immunogenicity of the group B polysaccharide and its
structural similarity to glycosylated host antigens has largely deterred the development of a group
B conjugate. Instead, emphasis has been on the use of outer membrane vesicles (OMVs) and the
identification of potential vaccine antigens using various “omics” techniques. This presentation will
review some of the key issues in the evaluation the MenC conjugates and look ahead to the
challenges posed by protein-based vaccine formulations.
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TB VACCINE DEVELOPMENT AND MANUFACTURING
Jerald C. Sadoff MD, Aeras Global TB Vaccine Foundation
1405 Research Blvd Suite 300, Rockville, Maryland, 20850, USA
T: 301 547 2912, F: 301 547 2901, jsadoff@aeras.org
John Fulkerson Ph.D., Aeras Global TB Foundation
Donata Sizemore Ph.D., Aeras Global TB Foundation
Eric Tsao Ph.D., Aeras Global TB Foundation
Bruce McClain M.D., Aeras Global TB Foundation
(Presented by Walter Kallaur)
There are currently around 2 billion people infected with TB with over 8 million new infections and
almost 1.6 million deaths each year. Multiple (MDR) and extreme (XDR) antibiotic resistance is
spreading. Although BCG is one of the worlds most widely used vaccines it does not prevent
pulmonary TB and has not curbed the worldwide pandemic. A new effective vaccine is the only
hope for elimination of TB. Modification of BCG by recombinant means to make it more
immunogenic and safer has been accomplished by introducing endosome escape through
expression of perfringolysin, introduction of pro-apoptotic factors such as Nuo G knockout,
incorporation of GMCSF cytokine expression and over-expression of TB antigens from various
stages of the TB organisms life cycle. New techniques for fermentation and stabilization have
been developed for this new generation of rBCG vaccines. A cGMP facility capable of producing
the worlds need (300 million doses/year) of bulk rBCG vaccine has been built and validated.
These rBCGs when used as primes for boost with non-replicating viral vectors have provided
non-human primate cellular immunogenicity and protection from challenge with TB. BCG prime
followed by viral vector boost has induced high levels of CD4+ and CD8+ T cell immunity in
humans. The human immunogenicity of these prime boost regimens makes this approach
feasible for other diseases requiring cellular immunogenicity such as Malaria and HIV. A network
of Vaccine trial sites for Phase II proof of concept testing in infants (Cape Town S.A.) and Phase
III efficacy testing for licensure in infants and adolescents/adults are being developed in South
Africa, Kenya, Uganda and India. It is anticipated that licensure of the first new TB vaccines in
over 80 years will occur in the 2015-16 time frame.
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EVALUATING NOVEL CELL SUBSTRATES FOR USE IN VACCINE MANUFACTURE
Philip R. Krause, M.D., FDA/CBER
29A/1C16, HFM-457, 29 Lincoln Drive, Bethesda, MD, 20892-4555, USA
T: 301-827-1914, F: 301-496-1810, philip.krause@fda.hhs.gov
Basic principles for evaluating cell substrates will be presented from a regulatory perspective.
Various novel cell substrate types, including tumorigenic cells and insect cells, will be used as
practical examples. New technologies that could improve assurance that products manufactured
in novel cell substrates are safe will also be discussed.
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EPITOPE-DRIVEN GAIA HIV VACCINE DEVELOPMENT: AN UPDATE
Anne S. De Groot, EpiVax
146 Clifford Street, PROVIDENCE, RI, 02903, USA
T: 401.272.2123, F: 401.272.7562, annied@epivax.com
Leonard Moise, Julie A. McMurry, Daniel S. Rivera, EpiVax
Ousmanne A. Koita, Karim Coulibaly, Universite' de Bamako, Mali
William D. Martin, EpiVax
Introduction. We set out to develop a globally-relevant epitope-based HIV vaccine composed of
CTL and helper T-cell epitopes that are highly conserved and immunogenic over a broad range of
HLA backgrounds.
Methods. All HIV protein sequences deposited in GenBank (1995-2002) were screened to create
a non-redundant database. Entries containing sequences >60% of the nominal protein length
were searched for conserved 9-mer segments using Conservatrix. 9-mers conserved in at least
5% of database sequences were analyzed by EpiMatrix for predicted binding affinity to six HLA
Class I and eight HLA Class II DR archetype alleles. Class II DR epitopes were extended to 2025 amino acids in length to create immunogenic consensus sequences (ICS) that are enriched for
overlapping conserved 9-mers with broad HLA coverage. Candidate HIV vaccine epitopes were
ranked by conservation and by putative affinity for HLA as measured by EpiMatrix z-score. Initial
evaluations of selected epitopes in ex vivo (human) and in vivo (mouse) studies have been
performed in Mali, Thailand and the USA.
Results. 5,494 highly conserved 9-mers were mined from a non-redundant database of 10,199
HIV protein sequences. Epitopes predicted to bind HLA class I and class II were generally more
broadly conserved than those selected for other epitope-based vaccines (>70%, compared to
Epimmune’s 40%). Interferon-gamma ELISpot assays performed in Providence, RI using PBMCs
obtained from HIV-infected subjects confirmed the antigenicity of both Class I (85% A2, 29% of
A3, 67% of B7, 20% of A24) and Class II ICS (95%) epitopes. Similar assays performed in Mali
and Thailand confirmed cross-clade recognition of these epitopes. Immunization of HLA A24 and
DR1 transgenic mice with multi-epitope vaccine formulations elicited robust epitope-specific T cell
responses to 3 out of 40 A24 and 7 out of 24 ICS epitopes tested.
Conclusions. Computational tools can be used to efficiently map epitopes and to incorporate
validated epitopes into vaccines. The GAIA HIV vaccine epitopes elicit robust, epitope-specific T
helper and CTL responses in HLA transgenic mice. These findings will serve as a springboard for
optimal immunogen engineering and targeting to boost multi-epitope vaccine immunogenicity and
efficacy.

Tuesday, June 3

Session 4

THE IMPROVED ISCOMATRIX® ADJUVANT
Debbie Drane, CSL Limited
45 Poplar Road, Parkville, Vic, 3052, Australia
T: +61 3 9389 1902, F: +61 3 9388 2063, debbie.drane@csl.com.au
The ISCOMATRIX® adjuvant is CSL’s proprietary biological vaccine adjuvant that has been
extensively refined and developed over a number of years. It is comprised of ISCOPREP®
saponin, cholesterol and phospholipid which combine to form cage-like structures typically 40nm
in diameter. It can then be formulated with virtually any antigen to produce an ISCOMATRIX®
vaccine. A range of ISCOMATRIX® vaccines have been tested in clinical trials and have been
generally safe and well tolerated as well as immunogenic, generating both antibody and T cell
responses. In recent years the focus at CSL has been on improving the ISCOMATRIX® adjuvant
which meets the ever increasing regulatory standards for components of human vaccines, whilst
maintaining the ability to induce strong immune responses. The result is an ISCOMATRIX®
adjuvant that is well defined, has minimal impurities and does not contain any materials of animal
origin. Improvements have also been made to the methods of manufacture to ensure the product
can be reliably produced at any relevant scale. Another area of recent activity has been to
increase the understanding of the mechanisms of action. The ISCOMATRIX® adjuvant has both
antigen delivery and immunomodulatory capabilities that combine to provide enhanced and
accelerated immune responses. The improvements to the ISCOMATRIX® adjuvant and
enhanced understanding of the science underpinning the mechanism of action should ensure that
the ISCOMATRIX® adjuvant will be an integral component in the development of novel human
vaccines that will facilitate manipulation of the body’s own immune system to prevent and/or treat
diseases that to date have been refractory to vaccination.
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ADJUVANTED PLASMID DNA-BASED VACCINES
Alain Rolland, Vical Incorporated
10390 Pacific Center Court, San Diego, CA, 92121-4340, USA
T: 858 646 1200, F: 858 646 1151, arolland@vical.com
Over the past few years, plasmid DNA prophylactic vaccines have reached licensure for
veterinary applications against viral infections such as infectious hematopoietic necrosis virus in
farmed salmons in Canada and West Nile virus in horses in the United States. In addition, a
therapeutic canine melanoma vaccine has received conditional approval in the US. Although
promising immunological results have also been reported in recent human clinical trials with
unadjuvanted DNA vaccines, for instance against Ebola and West Nile virus, a number of
approaches are being evaluated to further enhance the potency of DNA vaccines, including
formulation of DNA with adjuvants and administration of DNA with devices. This presentation
reports on a cationic lipid-based adjuvant, Vaxfectin®, which has shown enhanced immune
responses in a number of published animal studies using different routes of administration, with
the potential of dose-sparing activity for DNA vaccines. In particular, the nonclinical development
of a pandemic influenza DNA vaccine encoding conserved antigens and formulated with
Vaxfectin® will be presented. Plasmid DNA vaccines encoding hemagglutinin and conserved
influenza antigens represent an alternative approach that may overcome several of the limitations
of current licensed vaccines against seasonal and pandemic influenza, including dependence on
eggs for vaccine production, a relatively long manufacturing cycle, the need for yearly updates of
vaccine composition, the need for annual revaccination, reduced efficacy against HA-mismatched
strains and reduced overall efficacy in the elderly. Pandemic influenza DNA vaccine candidates
are currently being evaluated in two clinical trials by intramuscular needle and needle-free
administration and the studies design will be presented. The application of Vaxfectin® as an
adjuvant for protein-based vaccines will also be discussed and data supporting enhanced
immunogenicity and dose-sparing effect of Vaxfectin® will be presented.
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EXPLOITING GLYCOENGINEERED YEAST FOR THE DEVELOPMENT OF NEXT
GENERATION VACCINES
Robert C. Davidson, GlycoFi Inc., a wholly owned subsidiary of Merck and Co.
21 Lafayette St. Suite 200, Lebanon, NH, 03748, USA
T: 603-727-5116, F: 603-643-8194, robert_davidson@merck.com
Victoria Copeland, Stefan Wildt, Natarajan Sethuraman,
GlycoFi, Inc has developed engineered humanized yeast strains capable of producing
glycoproteins with human-like glycosylation. Unlike proteins obtained from mammalian cell
culture, which can by quite heterogeneous, GlycoFi’s engineered yeast secrete glycoproteins with
exceptional glycan uniformity. The ability to produce a glycoprotein with a predetermined
structure opens the door to systematically investigate glycosylation-dependent structure activity
relationships and to create specific glycoforms with improved therapeutic properties. By using a
variety of engineered yeast strains, a protein can be expressed with various glycoforms allowing
for elucidation and/or development of glycosylation-mediated functions. GlycoFi’s technology
further encompasses a combinatorial library for high throughput screening of fusion proteins and
promoters providing optimization of heterologous protein expression in yeast. For proteins that
prove difficult to express, this innovative method has proven to be quite successful in optimizing
the conditions for expression in a yeast host. Historically, viral subunit vaccine research and
development often requires production of difficult to express glycoproteins. Proper folding, highlevel secretion, and function can all be affected by N-glycosylation, and the nature of Nglycosylation can differ dramatically in many heterologous protein production hosts from that of
the native protein. Application of GlycoFi’s humanized yeast technology can provide a range of
benefits to improve the lead identification and optimization of subunit vaccines. Furthermore,
manufacture of subunit vaccines with highly immunogenic N-glycans, such as alpha-1,3galactose can now be contemplated.
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ENHANCING VACCINE IMMUNOGENICITY THROUGH USE OF CPG TLR9 AGONISTS AND
OTHER ADJUVANTS
Risini D. Weeratna, Ph.D., Coley Pharmaceutical Group
340, Terry Fox Drive Suite 200, Ottawa, Ontario, K2K 3A2, Canada
T: (613) 254-5622 Ext 3144, F: (613) 254-5625, rweeratna@coleypharma.com
Synthetic oligodeoxynucleotides containing CpG motifs (CpG ODN) are ligands for Toll-like
Receptor 9 (TLR9) that is found in the endosomal compartment of human B cells and
plasmacytoid dendritic (pDC) cells. Direct activation of B cells and pDC through TLR9 can lead to
potent innate immune activation. In addition to innate immune activation, in the presence of an
antigen, CpG ODN can promote the induction of strong Th1 biased immune responses.
Stimulation of B cells by CpG ODN in the presence of antigen can selectively enhance the
development of antigen-specific antibodies, especially of the isotype associated with Th1-like
immune responses (e.g., IgG2a in mice). Following CpG ODN stimulation, both B cells and DC
can effectively present antigen to T cells. CpG-induced antigen presentation taking place in a
Th1-like cytokine milieu can lead to induction of strong Th1 biased immune responses consisting
of cell-mediated as well as humoral immunity.
According to preclinical data CpG ODN are effective in augmenting the kinetics and strength of
both antibody and cell-mediated responses to virtually all types of antigens. They are effective
adjuvants in hyporesponsive populations and in neonates even in the presence of maternally
derived antibodies. CpG ODN are also effective adjuvants in mucosal vaccines and promote the
induction of strong IgA responses both at local and distal mucosal sites. Use of CpG ODN as
adjuvants allows antigen dose sparing and earlier boosting. Furthermore, CpG ODN can be used
in combination with a wide variety of other adjuvants with the combinations showing either
synergistic or additive effects.
CPG 7909 (VaxImmune) induced faster and stronger titers of higher avidity antibodies to a
commercial hepatitis B vaccine (Engerix-B, GlaxoSmithKline) in normal volunteers. Similar results
were found in a subsequent trial conducted in HIV infected subjects who failed to respond to
previous vaccination with proportion of subjects remaining seroprotected being significantly
greater in the CpG group compared to the controls even 5 years later. In other Phase I clinical
studies, enhancement of the strength and kinetics of antibody responses were found with addition
of CPG 7909 to either the Biothrax whole killed AVA anthrax vaccine (Emergent), or recombinant
malaria vaccines containing either Plasmodium falciparum AMA1 or MSP1 adsorbed to alum
(Malaria Vaccine Development Branch, NIAID).
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QUALITY ASSESSMENT OF CERVARIXTM, GSK’S CERVICAL CANCER VACCINE ,
MANUFACTURED WITH THE BACULOVIRUS EXPRESSION VECTOR SYSTEM (BEVS)
Marguerite Deschamps, GlaxoSmithKline Biologicals
89, rue de l'Institut, Rixensart, /, 1330, Belgium
T: 32-5.656.93.54, F: 32-5.656.81.33, marguerite.deschamps@gskbio.com
CervarixTM, GlaxoSmithKline Biologicals’ (GSK) cervical cancer vaccine is a recombinant vaccine
composed of human papillomavirus (HPV)-16/18 L1 virus-like particles (VLP) adjuvanted with the
proprietary AS04 adjuvant system. CervarixTM has been shown in phase II clinical trials to provide
sustained antibody responses for HPV-16 and 18 and prevention of abnormal cytology and
cervical neoplasia up to 5.5 years [Gall 2007, Harper 2007]. In phase III clinical trials, the cervical
cancer vaccine has been shown highly efficacious against high grade cervical neoplasia caused
by HPV-16 and HPV-18 in a broad population of women and to prevent 6-month persistent
infections against non-vaccine HPV types (HPV-45 and 31) [Paavonen 2007].
GSKs HPV vaccine antigens were manufactured with the baculovirus expression vector system
(BEVS) using recombinant baculoviruses genetically engineered to carry the capsid HPV-16 and
HPV-18 L1 gene and express the L1 proteins in a qualified cell line derived from Trichoplusia ni.
The use of the BEVS for prophylactic HPV antigen vaccine production prompted the development
of a specific quality control and characterisation testing programme. Classical quality control in
combination with BEVS adapted testing (e.g specific permissive cell lines and PCR) at different
levels of the vaccine manufacture substantiates the quality of the BEVS for human vaccine
antigen production.
Highly purified, well-characterized and immunogenic L1 VLPs are obtained following protein
extraction and purification through a multistage process. The structural integrity and similarity of
the L1 VLPs to the native HPV virions was documented through morphological and antigenic
analysis.
Overall, quality assessment results show that the BEVS technology can be used to manufacture
controlled, well-characterized, safe and scalable HPV vaccine. These results demonstrate that
GSKs BEVS technology is an effective expression system for the large scale manufacturing of
efficacious, safe, and immunogenic HPV recombinant vaccines.
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CHARACTERIZATION OF CONJUGATE VACCINES
Rasappa Arumugham, Wyeth Vaccines Research and Development
4300 Oak Park, Sanford, NC, 27560, USA
T: 919 294 1502, F: 919 294 1887, Arumugr@wyeth.com
Kun Yao, Wyeth Vaccines Research and Development
John Kim, Wyeth Vaccines Research and Development
Erin Laskowich, Wyeth Vaccines Research and Development
Suddham Singh, Raymond Kaiser, Wyeth Vaccines Research and Development
Conjugate vaccines are produced by covalently attaching an antigen to a carrier protein in order
to improve the effective immune response of the vaccine. The resulting antigen-to-carrier protein
conjugate are often quite complex relative to a typical therapeutic protein or glycoprotein. Recent
innovations in analytical technologies have allowed for more detailed characterization of vaccine
conjugates and their intermediates. Analytical characterization of a conjugate vaccine against
Streptococcus pneumoniae will be presented.
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CHARACTERIZATION OF ADENOVIRAL VECTOR-BASED VACCINES
Katey Einterz Owen, Ph.D., Merck & Co., Inc.
770 Sumneytown Pike, P.O. Box 4, West Point, PA, 19486, USA
T: 1-215-652-6061, F: 1-215-993-3400, Katherine_Owen@merck.com
Recombinant replication-deficient adenoviral vectors have been used as a platform for vaccine
development against various targets at Merck. In order to evaluate the safety and efficacy, and
support process development of these candidate vaccines, we have developed an array of
analytical methods to characterize various properties of the vaccines, including purity, identity,
potency, and mass. Results from those key assays will be shown to illustrate various attributes of
process intermediates, purified bulk, and final-container products. Data from the product
characterization, stability studies, and process monitoring will be presented. Furthermore, the
correlation between the results of in vitro cell based potency assays and human immunogenic
response observed in the clinic will be reviewed.
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FOCUS ON AGGREGATION: CAUSES, IMPACT, AND CHARACTERIZATION
John S. Philo, Alliance Protein Laboratories, Inc.
3957 Corte Cancion, Thousand Oaks, CA, 91360, USA
T: 805-388-1074, F: 805-388-7252, jphilo@ap-lab.com
Aggregation is often a significant degradation pathway for biologics. For vaccines, on the other
hand, some aggregation (self-association) may be necessary for activity (as in VLPs), so
reproducibility of such desirable association may be critical for product quality. This talk will
review the types and causes of aggregation, and why characterization methods in addition to
SEC are often requested by the regulators. Advanced methods for characterization of
aggregation will be described, including analytical ultracentrifugation (AUC), light scattering (SECMALLS), and FFF. The advantages and disadvantages of these techniques will be discussed,
along with real-world examples and applications.
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DEVELOPING IN VITRO POTENCY ASSAYS TO MONITOR PROCESS DEVELOPMENT AND
STABILITY FOR SUBUNIT VACCINE
Ying Zhang, Wyeth Vaccines
407 Davis Drive, Durham, NC, 27713, USA
T: 919-294-1454, F: 919-294-1883, zhangy4@wyeth.com
Ray Kaiser, Wyeth Vaccines
Rasappa Arumugham, Wyeth Vaccines
Potency is one of most important quality attributes for bio products, especially for vaccine
products. Functional assays such as plaque neutralization assays are commonly available for a
number of viral vaccine candidates. However, there is no effective potency assay platform
technology available for bacterial subunit vaccine programs. Here we will describe the
development of platform technology that can be utilized for all bacterial vaccines. This technology
comprises of selecting appropriate biologically relevant functional monoclonal antibodies directed
against the conformational epitopes of a vaccine antigen coupled with homogenous
immunoassay techniques. Based on ICH guidelines, all 6 qualification-parameters including
specificity, linearity, repeatability, precision, accuracy, and robustness have been evaluated.
Using the developed potency assay, we were able to monitor conformational structure of
recombinant proteins during process and formulation changes. We’ll present the assay format
and show examples how these assays are used in the evaluation of process and formulation
development as well as monitoring the stability of these products.
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CHALLENGE OF FILING 4 NEW VACCINES AT ONCE
Keith Chirgwin, Merck
PO Box 1000, North Wales, PA, 19454, US
T: 267-305-6723, F: 267-305-6407, keith_chirgwin@merck.com
Lessons learned during recent regulatory review and approval of four vaccines will be reviewed.
Overlapping and concurrent reviews of these four applications by multiple agencies worldwide
required planning and sequencing of activities to support key milestones during regulatory review,
such as FDA Advisory Committee Meetings and responses to questions in the EU and other
agencies. Obtaining regulatory agency concurrence with development plans at appropriate
stages of development was a key enabler of successful review. Important areas for early agency
concurrence included: clinical endpoint validation, clinical protocol design, statistical analysis plan
and criteria for success, assay validation, and analytical development plans for product
characterization and release testing. Agreement should be obtained with the approach to
endpoint validation prior to pivotal efficacy trials; this is particularly important for novel clinical
endpoints. Similarly, for vaccines where licensure relies on comparisons of immunogenicity,
agreement should be obtained regarding assay validation and criteria for success prior to
finalizing the design of phase III trials. Gaining agreement with the rationale and approach to
analytical development and product characterization, and ultimately release testing and
comparability protocols, may be facilitated by early discussions with regulators. Development of
risk management plans should start well before submission of the marketing application and
include a careful assessment of the capacity of potential investigators to support completion of
post-licensure study commitments within agreed upon timeframes.

Wednesday, June 4

Session 6

PATH: NARROWING THE IMMUNIZATION GAP
Dr. John W. Boslego, PATH
1800 K Street, NW, Suite 800, Washington, DC, 20006, USA
T: 202-822-0033, F: 202-457-1466, jboslego@path.org
Dr. Boslego’s presentation, PATH: Narrowing the Immunization Gap, will illuminate the breadth of
work on vaccines and immunization at PATH and show how nongovernmental organizations
(NGO) can impact global public health. The presentation will discuss how an NGO can increase
availability of vaccines for developing world populations, work to decrease the lag time in
adoption of a vaccine between the developed and developing worlds, and work to further the
development of a vaccine candidate through research and development. These topics will be
highlighted through examples of PATH projects on vaccines and immunization.
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VIRAL VECTORS FOR GENETIC VACCINATION: STRATEGIES, VECTOR DESIGN AND
PRODUCTION

J.A. Asenjo, Centre for Biochemical Engineering and Biotechnology, Institute for Cell Dynamics
and Biotechnology (ICDB) , University of Chile
Beauchef 861, Santiago, Chile
T: 56-2-978 4723, F: 56-2-699 1084, juasenjo@ing.uchile.cl
V. Martinez, Z.P. Gerdtzen, Centre for Biochemical Engineering and Biotechnology, Institute for
Cell Dynamics and Biotechnology (ICDB) , University of Chile
E. Karahanian, Gene Therapy Laboratory, Institute for Cell Dynamics and Biotechnology (ICDB) ,
University of Chile
B.A. Andrews, Centre for Biochemical Engineering and Biotechnology, Institute for Cell Dynamics
and Biotechnology (ICDB) , University of Chile
Y. Israel, Gene Therapy Laboratory, Institute for Cell Dynamics and Biotechnology (ICDB) ,
University of Chile
We have developed different strategies for gene therapy treatment as well as optimized vector
production and purification systems for large scale virus production. Our first strategy consists of
using first and third generation adenovirus vectors (also called “gutless” or helper dependant),
which have been completely stripped of the sequences coding for the viral proteins and have
dramatically reduced immunogenicity. Adenoviral vectors (Δ E1, E3) have been used to induce
inhibition of the mitochondrial aldehyde dehydrogenase gene using an antisense mechanism.
The two genes responsible for enzymes that metabolize ethanol and oxidize acetaldehyde greatly
influence the development of alcohol dependence. Rat lines bred as alcohol drinkers decreased
their ethanol intake by 50-60% after treatment with the adenovirus vectors. A second strategy,
that avoids possible activation of oncogenes, considers ex-vivo treatment of bone marrow cells
where the appropriate gene is integrated into the genome.
Culture optimization and scale-up for the HEK293 cell line used for the production of adenovirus
vectors has been achieved by first adapting the cells to serum-free media and secondly by
growing them in suspension where they form aggregates with increased cell concentration.
Adenovirus production after infection was therefore increased, resulting in higher specific glucose
consumption and lactate accumulation rates compared to the growth phase. We applied media
design tools and Metabolic Flux Analysis (MFA) to compare the metabolic states of cells during
growth and adenovirus production and to optimize culture media according to the metabolic
demand of the cells in terms of glucose and glutamine concentrations. This allows us to obtain
higher maximum cell concentrations and increased adenovirus production by minimizing the
production of metabolites that can have an inhibitory effect on cell growth. MFA results allowed us
to determine how these changes in composition affected the way cells distribute their nutrient
resources during cell growth and virus production. Virus purification was successfully achieved
using chromatography and Aqueous Two-Phase Systems (ATPS).
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CONTROLLING IN VITRO ASSEMBLY OF VIRUS-LIKE PARTICLES: FROM THEORY TO
EXAMPLE
Adam Zlotnick, University of Oklahoma Health Sciences Center
PO Box 26901, BRC464, Oklahoma City, OK, 73104, USA
T: 405-271-9030, F: 405-271-3910, adam-zlotnick@ouhsc.edu
Virus capsid self-assembly is critical for virus biology and has potential as a target for antivirals.
Virus-like particles (VLPs) are now vaccines and have potential as platforms for extra-viral
antigens and as decoys. Expression systems do not always yield VLPs adequate for a given
application. In vitro reassembly is a powerful strategy that can be facilitated by an understanding
of the physical chemistry of self-assembly and the biochemistry of the specific viral proteins. In
general, successful assembly is based on a nucleated cascade of weak association reactions.
Unsuccessful reactions tend to have strong interactions leading to kinetically trapped aggregates.
Though individual interactions are weak, closed spherical particles can persist in a metastable
manner due to hysteresis to dissociation derived from their lack of ÒlooseÓ ends. With hepatitis
B virus, an important pathogen in its own right and a potential platform for epitopes, these
principles are demonstrated with successful assembly reactions and in (putative) drug-induced
misassembly. With human papilloma virus type 16, for which VLPs are a component of antiviral
vaccines, we find that weak interactions lead to uniform and stable particles whereas strong
interactions lead to the predicted kinetic trap. These observations suggest a general strategy for
identifying reassembly conditions.
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VIRUS LIKE PARTICLES AS VACCINE PLATFORMS
Bryce Chackerian, University of New Mexico
Dept. of Mol. Genetics and Micro, MSC08-4660, Albuquerque, NM, 87131, USA
T: (505) 272-0269, F: (505) 272-6029, bchackerian@salud.unm.edu
Virus-like particles (VLPs) can be considered as dense repetitive arrays of one or more protein
subunits with properties that are highly advantageous for use as stand-alone vaccines or as
platforms for the induction of antibody responses against heterologous antigens. In this talk, I will
discuss the how VLPs have been used to increase the immunogenicity of diverse target antigens,
including self-antigens. I will give an overview of the techniques for presenting diverse target
antigens on VLPs including our recent development of a platform for vaccine development based
on the VLPs of RNA bacteriophage MS2. This new platform serves for the engineered display of
specific peptide sequences, but will also allow the construction of random peptide libraries from
which specific binding activities can be recovered by affinity selection. I will also present some
recent data that demonstrates how both antigen valency and the availability of T cell help play
quantitative roles in the induction of antibody responses. For foreign antigens, we have shown
that these factors are important in determining the magnitude of the antibody response. For selfantigens, antigen multivalency and the availability of T help are critical factors that modulate the
ability to induce anti-self responses in the face of B cell tolerance mechanisms.
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ALTERNATE ROTAVIRUS VACCINES: INACTIVATED VIRUS AND VLPS
Conner, ME, Baylor College of Medicine and MED VAMC, Houston, TX 77030
BCM MSC 385, Dept MVM, One Baylor Plaza, Houston, TX, 77030, USA
T: 713-798-3590, F: 713-798-3586, mconner@bcm.edu
Blutt, SE, Baylor College of Medicine
Marcelin, G, Baylor College of Medicine
Crawford, SE, Baylor College of Medicine
Estes, MK, Baylor College of Medicine
Rotavirus is the leading cause of severe dehydrating diarrhea in young children worldwide
resulting in approximately 600,000 deaths annually. The majority of these deaths occur in subSaharan Africa and Asia. Two licensed live attenuated oral rotavirus vaccines are highly
efficacious in preventing diarrhea in developed countries but these vaccines have not yet been
tested in countries with high mortality rates from rotavirus infection. Historically, live oral vaccines
are much less efficacious in these settings, which is attributed to multiple factors including,
prevalence of (i) maternal antibodies, (ii) pathogenic organisms in the intestine, and (iii)
malnourishment. Therefore, it is unlikely that the live rotavirus vaccines will be highly efficacious
in sub-Saharan Africa and Asia leaving a need to develop alternate rotavirus vaccine strategies
that would be safe and efficacious in these settings. Vaccines administered by intramuscular (IM)
route are an alternate vaccination strategy that may work well in such settings. Maternal
vaccination of pregnant mothers by this route may also provide a means to protect young children
from severe rotavirus infections. We utilized three animal models of rotavirus infection (mice,
rabbits, cows) to assess in pre-clinical studies whether IM immunization with VLPs or inactivated
virus induced active or passive protection from rotavirus infection. Multiple formulations of viruslike particles (VLPs) were produced using the baculovirus expression system. In mice and
rabbits, active immunization with VLPs or inactivated virus, induced high levels of rotavirusspecific antibodies in both the serum and the intestine and vaccinated animals were highly
protected from rotavirus infection. In mice, protection was mediated by rotavirus-specific IgA in
the intestine. Importantly, VLPs induced broader and stronger heterotypic neutralizing antibody
responses than live oral rotavirus infection, suggesting that VLPs might induce broader and
stronger heterotypic protection. In cows, VLPs induced passive protection through the milk.
Multiple new genotypes of rotavirus have emerged in recent years and in some developing
countries these strains have become prevalent. A VLP vaccine would be advantageous because
VLPs based on these new strains could be developed more rapidly and development of localespecific vaccines would be feasible. Therefore, VLPs administered intramuscularly provide a
promising alternate rotavirus vaccine candidate that may prove efficacious in those developing
countries where the rotavirus mortality rates are high.
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TOWARDS A RESPIRATORY SYNCYTIAL VIRUS VACCINE USING RECOMBINANT F
PROTEIN TRANSIENTLY EXPRESSED IN MAMMALIAN CELLS
Sophie Nallet, École Polytechnique Fédérale de Lausanne (EPFL), Institute of Bioengineering,
Laboratory of Cellular Biotechnology
Station 6, Lausanne, CH-1015, Switzerland
T: +41 21 693 61 37, F: +41 21 693 61 40, sophie.nallet@epfl.ch
Lucia Baldi, David L. Hacker, Florian M. Wurm, École Polytechnique Fédérale de Lausanne
(EPFL), Institute of Bioengineering, Laboratory of Cellular Biotechnology, CH-1015 Lausanne,
Switzerland
Iwo König, Christiane Zaborosch, Zürcher Hochschule für Angewandte Wissenschaften, Institute
of Chemistry and Biological Chemistry, Laboratory of Biochemistry, CH-8820 Wädenswil,
Switzerland
Nicole Westerfeld, Mario Amacker, Rinaldo Zurbriggen, Pevion Biotech Ltd., CH-3018 Bern,
Switzerland
Markus Hildinger, ExcellGene SA, CH-1870 Monthey, Switzerland
Respiratory syncytial virus (RSV) is regarded as the most important cause of viral lower
respiratory tract illness during infancy and early childhood worldwide. It is also recognized as a
significant problem in the elderly. However, no RSV vaccine is currently available. Early studies
demonstrated the efficacy of the RSV-F protein (RSV-F) for inducing high titers of neutralizing
antibodies, but the purification of RSV-F from virus is difficult and hampered by considerable
safety concerns.
We are developing an RSV vaccine based on the transient expression of recombinant RSV-F in
mammalian cells and its formulation into immunostimulating reconstituted influenza virosomes
(IRIVs). Transient gene expression in suspension cultures of mammalian cells at volumes
exceeding laboratory-scale operations (Baldi et al., Biotechnol Lett. 2007, 29(5):677-84) is a
technology that allows the production of properly folded and glycosylated proteins in a
considerably shorter time than from stable cell lines, significantly reducing costs for research and
development. The codon-optimized RSV-F gene was transiently expressed in HEK293 cells
adapted to serum-free suspension growth. The presence of the protein on the cell surface was
confirmed by immunostaining. The production process was optimized in 10 mL cultures within
ventilated, orbitally shaken 50 ml tubes as developed by ExcellGene SA (TubeSpin®). The
optimized procedure was then performed in actively ventilated, orbitally shaken 20 L plastic
7
biotainers, yielding up to 20 mg/L of recombinant RSV-F or about 1 x 10 copies of RSV-F trimer
per cell. Recombinant RSV-F was purified by affinity chromatography, formulated into virosomes,
and administered to Balb/C mice for immunogenicity studies. Recombinant RSV-F production and
purification processes are currently in development for scale-up in order to prepare sufficient
material for a challenge study in cotton rats and for clinical trials in humans. If successful, this
would be the first vaccine generated with a recombinant protein produced by large-scale transient
gene expression in mammalian cells. Results of the optimization study, as well as the in vivo
animal experiments, will be presented and discussed.
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A SELECTIVE RECOVERY METHODOLOGY FOR THE CLARIFICATION OF LIPIDENVELOPE VIRUS-LIKE PARTICLES FROM S. CEREVISIAE
Gaik Sui Kee, University College London
Advanced Centre of Biochemical Engineering, University College London, Torrington Place,
London, WC1E 7JE, United Kingdom
T: +44 (0) 20 7679 4410, F: +44 (0) 20 7916 3943, ucbegsk@ucl.ac.uk
Narahari Pujar, Merck & Co. Inc
Nigel Titchener-Hooker, University College London
The recovery of virus-like particles (VLPs) expressed in Saccharomyces cerevisiae requires a
multistage operation and the purification process is particularly challenged by the high levels of
contaminants in the process stream. Lipid-envelope VLPs often remain localized on cell
organelles after expression and the recovery process requires the use of a detergent to release
the VLPs into the product stream. This study demonstrates the potentials of a clarification
strategy for lipoprotein VLPs whereby an additional centrifugation step is introduced after cell
disruption to allow selective VLP recovery during the detergent step. The studies, using the
Hepatitis B Surface Antigen (HBsAg) as the model VLP, showed that almost all the VLP product
remain associated with the pellet fraction. Detergent treatment of the pellet fraction achieved
HBsAg product recovery of over 95% which is consistent with the findings of Chi et al, 1994. This
approach allows the elimination of cytosolic material in the supernatant fraction containing bulk
cell protein, lipid and nucleic acids contaminants, giving a product enrichment factor of ~3.
Investigations on homogenisation conditions showed that the efficiency of the selective recovery
approach could be further enhanced by the use of moderate homogenisation pressures in the
region of 400 bar. Under these pressure conditions, better recovery of active HBsAg was
observed as well as an improvement in lipid clarification. This is because minimal cell
fragmentation at lower pressures leads to reduced co-liberation of host lipid contaminants during
the detergent step. The value to the selective recovery methodology to a downstream
hydrophobic interaction chromatography (HIC) process was also demonstrated. Owing to the
reduced level of contaminants, product capture improved resulting in higher chromatography step
yield.
Reference: Chi, W., Ku, C.H., Chang, C., Tsai, J.; Two-step cell disruption for extraction of
membrane-associated recombinant protein from Saccharomyces cerevisiae. Ann N Y Acad. Sci.,
1994, 2, 721: 365-73
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CONSIDERATIONS FOR USE OF THE 'ANIMAL EFFICACY RULE'
Karen L. Goldenthal, M.D., Independent Consultant
5015 Battery Lane, Bethesda, MD, 20814, USA
T: 301-656-8396, F: 301-656-8396, kgoldenthal@comcast.net
In 2002, US FDA published a Final Rule amending its regulations to allow appropriate studies in
animals in certain cases to provide substantial evidence of the effectiveness for biological
products (including vaccines) and new drugs (Federal Register 2002;67:37988-98;
http://www.fda.gov/cber/rules/humeffic.pdf). This rule (sometimes referred to as the “animal
efficacy rule”) will apply only when adequate and well-controlled clinical trials in humans cannot
be ethically conducted and clinical field efficacy studies are not feasible. Under this Rule, animal
data can be used to provide evidence of efficacy only if all of the following criteria are met: (1)
There is a reasonably well understood pathophysiological mechanism of toxicity of the substance
and its prevention or substantial reduction by the product; (2) The effect is demonstrated in more
than one animal species (some exceptions) expected to react with a response predictive for
humans; (3) The animal study endpoint is clearly related to the desired benefit in humans; and (4)
Relevant data (e.g., kinetics) allow selection of an effective human dose. This rule will not apply if
approval can be based on standards described elsewhere in FDA regulations. Also, vaccine
immunogenicity and safety data will be needed from human clinical trials.
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DE-RISKING VACCINE DEVELOPMENT: CORRELATES OF SUCCESS
Fiona MacLaughlin, The Wellcome Trust
Technology Transfer, 215 Euston Road, London, NW1 2BE, UK
T: 020 7611 8310, F: 020 7611 8857, f.maclaughlin@wellcome.ac.uk
The Wellcome Trust is an independent research-funding charity with the mission to foster and
promote research with the aim of improving human and animal health. We support R&D across a
diverse range of technologies, including vaccination, diagnostics, therapeutics and regenerative
medicine. In relation to vaccination, we fund all stages of the research process, from basic
investigations into infection and immunology, to product-oriented R&D. Through our Translation
Award funding scheme, institutions or companies can seek support for product development at
key stages of the product life-cycle where the aim is to ensure innovative medical technologies
will be developed to satisfy an unmet medical need. Normally, our support for product R&D
focuses on the demonstration of proof-of-concept, with the expectation that the research can be
advanced to a stage at which it will attract further funding from the investment community,
industry, or product-development Public-Private Partnerships. Examples of vaccine projects that
have secured Translation Award funding will be presented.

Wednesday, June 4

Session 7

AGE1.CR – A WELL CHARACTERIZED CELL SUBSTRATE DESIGNED FOR PRODUCTION
VECTOR BASED VACCINES
Volker Sandig, ProBioGen AG
Goethestrasse 54, Berlin, Berlin, 13086, Germany
T: +493092400670, F: +493092400619, volker.sandig@probiogen.de
Dr. Ingo Jordan, ProBioGen AG
Dr. Adriaan Vos, IDT-Biologika GmBH
Dr.Andreas Neubert, IDT-Biologika GmBH
The permanent cell lines AGE1.CR and its derivative AGE1.CR.pIX were developed by
transfection of primary cells of a muscovy duck embryo with defined combinations of
immortalizing genes (E1A, E1B 55k and E1B 19K). The focused biochemical approach allowed
us to use defined tissue samples from a single duck embryo rather than a mixture of cells from a
pool of embryos – thereby reducing the risk of contamination and facilitating documentation. The
approach is consistent with the “defined risk” guidelines issued by the FDA for the generation of
new cell substrates for application in the production of live vaccines because the immortalizing
genes are known and traceable. Stable expression of the E1 transgenes for over 3 years in the
absence of selection pressure indicates that the transgenes (rather than a spontaneous event)
are responsible for the immortal phenotype of the developed cells. Master cell banks were
established and extensively tested following EMEA and FDA guidelines taking the 2006 Draft
Guidance for Industry into account. The cell lines are adapted to growth as a single-cell
suspension or in aggregates facilitating virus production in fermenters (stir tank, Wave) without
the requirement for animal-derived components in the media. A peak doubling time of 25h and a
maximum cell density of 9 x 106 cells/ml provide the basis for efficient production processes. As a
permanent cell line AGE1.CR offers the opportunity for stable transfection of additional genes.
We show how introduction of the adenovirus pIX gene modulates cell metabolism and enhances
susceptibility to attenuated virus strains and vectors. Transfer of essential viral functions into the
cell line provides the basis for a production platform for inactivated viral vectors.
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EMERGING DISEASES, ZOONOSES, AND VACCINES TO CONTROL THEM
Pastoret, Paul-Pierre, World Organisation for Animal Health (OIE)
Publications Department, 12, rue de Prony,, n/a, Paris, 75017, France
T: n/a, F: n/a, pp.pastoret@oie.int
Disease control is more complex when facing emerging or re-emerging infections, particularly
zoonotic ones; for instance, the emergence of canine parvovirosis posed a serious threat to
animal health. The first step was to vaccinate dogs with a vaccine directed against feline
panleukopaenia, since the two causative viruses are antigenically nearly identical. This first step
was rapidly followed by the development of vaccines, either inactivated or attenuated, specifically
directed against canine parvovirosis. Developing vaccines is more problematic when facing
outbreaks of diseases caused by viruses showing broad antigenic diversity, such as Foot-andmouth disease virus or Bluetongue virus (in this latter case disease control is even more difficult
due to the fact that the infection is transmitted by a Culicoides vector (biting midges). Following
the first outbreak of bluetongue in northern Europe it was two years before inactivated vaccines
against serotype 8 of Bluetongue virus were available. However, in North America, the
spectacular spread of West Nile virus infection, another vector-transmitted disease, in humans
and horses was rapidly followed by the development of several vaccines for horses, including a
DNA-based vaccine. One solution to being ready to vaccinate in the face of an outbreak is to
stockpile vaccines, as exemplified by the storing of Foot-and-mouth virus vaccines as
concentrated antigens. Stockpiling is also envisaged in preparation for the possible pandemic of
avian influenza H5N1 in humans and to mitigate the risk of bio-agro-terrorism. For the time being,
however, efforts should be focused on eradicating the infection at the animal source by
vaccination to prevent human exposure. One of the best examples of this concept is wildlife
vaccination against rabies. Sometimes, animals are vaccinated against certain infections not
principally for their own sake, but to prevent human contamination. For instance animal
vaccination may be used to prevent food poisoning, e.g. a vaccine against Escherichia coli
0157:H7 has recently been conditionally approved for cattle in the United States. A large number
of pathogens are zoonotic and infect multiple animal species. Moreover, approximately 75% of all
diseases, including zoonoses, which have emerged in the last few decades are of wildlife origin.
Animal vaccination will continue, therefore, to play an important role in safeguarding animal and
human healths in the future.
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AVIAN INFLUENZA VACCINE DEVELOPMENT: APPLICATION TECHNOLOGY
PLATFORMS, FIELD USE AND PREDICTORS OF PROTECTION
David E. Swayne, U.S. Department of Agriculture, Agricultural Research Service, Southeast
Poultry Research Laboratory
934 College Station Road, Athens, Georgia, 30605, USA
T: 706-546-3433, F: 706-546-3161, David.Swayne@ars.usda.gov
Vaccines against avian influenza (AI) began over 100 years ago as experimentally produced
products, but commercial application did not occur until: 1) a reliable method was developed to
grow and titer the virus (i.e. embryonating chicken eggs), 2) an efficient and predictable method
was developed to inactivate the virus without destroying antigenic epitopes (i.e. formalin
inactivation), and 3) a method was developed to enhance the immune response (i.e. oil emulsion
adjuvants). Commercial usage of vaccines began in 1979 with limited usage of inactivated oilemulsion vaccines for low pathogenicity avian influenza (LPAI) in meat and breeder turkeys. AI
vaccine usage increased in the mid-1990s with H9N2 LPAI in developing countries, and the first
usage of AI vaccines against high pathogenicity (HP) AI occurred following large scale outbreaks
of H5N1 HPAI in Mexico and H7N3 in Pakistan. For the latter two epizootics, over 4 billion doses
have been used in 10 years. However, the greatest quantity of AI vaccine used has been in
response to the emergence of the H5N1 HPAI epizootic in Asia, Africa and Europe. The actual
quantity of vaccine used is unknown, but from conservative estimates the amount has exceeded
30 billion doses since 2002. Over the past 40 years, AI vaccines have been primarily based on
LPAI and HPAI viruses used in inactivated, oil emulsified vaccines. Recently, fowl poxvirus and
avian paramyxovirus type 1 vectored vaccines with AI H5 gene inserts have been developed and
licensed in some countries. Advances in biotechnologies may overcome some existing limitations
and result in vaccines that can be grown in tissue culture systems for more rapid vaccine
production; provide optimized protection as the result of closer genetic relationship to field viruses
through rapid changing of AI hemagglutinin gene insert through cassette concept; can be mass
applied by aerosol, drinking water or in ovo administration; and provide easier strategies for
identifying infected birds within vaccinated populations. These rising technologies include AI
viruses with partial gene deletions, AI-ND virus chimeras and vectored vaccines using
adenoviruses, Marek’s disease, or sub-unit vaccines. An additional benefit of some vectored
technologies is a broad application in multiple animal species. For example, fowl poxvirusvectored vaccines have shown efficacy in chickens, geese and cats. There potential use in the
field will also be determined on the requirement for low cost vaccines to be economically
competitive. In addition, the vectored vaccines can be used to enhance immune response using a
prime-boost two vaccine application protocol.
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USE OF ALTERNATE HOSTS IN THE MODELING OF IMMUNE PROFILING AND VACCINE
RECOGNITION
Lorne A. Babiuk, University of Alberta
Vice-President (Research), 3-7 University Hall, Edmonton, AB, T6G 2J9, Canada
T: 780-492-5353, F: 780-492-3189, lorne.babiuk@ualberta.ca
Advances in molecular biology and immunology have resulted in the rapid identification of specific
antigens of many pathogens that can induce protective immune responses in mice. However, it is
becoming well known that these data cannot always be translated to success in large animals or
humans. This is especially the case in neonates – those most vulnerable to infections. Thus the
choice of animal models for such studies is extremely critical. It is our belief that the most
effective animal models will those in which the pathogenesis of the infection agent is identical or
very similar to what happens in humans (i.e., a natural infection). The collateral advantage of
using appropriate animal models is the system can also lay the foundation for protecting the
animal species from the disease of interest. However, even with the best model and the best
vaccine antigens if a vaccine is not formulated and delivered properly, the vaccine will not
achieve its full potential. The current presentation will describe the use of large animal models
(pig and calf) to complement mouse models in testing a series of novel immune modulators (CpG
and host defence peptides) in combination with the delivery vehicle (poly phosphazene) to
enhance the magnitude and modulate the quality of immune response to a variety of different
vaccine antigens. We will demonstrate that these formulations can be delivered internasally to
induce mucosal immune responses as well as being able to develop appropriate immune
responses that protect animals from infection.
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USE OF PLASMID DNA VACCINE TO TREAT MELANOMA IN DOGS
Jedd Wolchok, MD, PhD, Clinical Immunology Svc, Melanoma Section, Memorial Sloan-Kettering
1275 York Avenue, New York, NY, 10021, USA
T: (212) 639-6570, F: (212) 794-4352, wolchokj@mskcc.org
(Presented by Robert Nordgren)
Immune responses to antigens found on cancer are usually constrained by tolerance to the
largely ‘self’ molecules which are presented. Immunization using homologous antigens from a
different species, so-called xenogeneic immunization, is one means to overcome the immune
system’s reluctance to adequately recognize these targets. We have developed plasmid DNA
vaccines encoding human and mouse tyrosinase, a prototypical differentiation antigen expressed
by most malignant melanomas and normal melanocytes. Preclinical mouse studies showed the
injection of human tyrosinase DNA vaccines in C57BL/6 was able to induce CD8+ T cell and
antibody responses to mouse tyrosinase capable of mediating protection from syngeneic tumor
challenge. Based on these data, a clinical trial program was developed at the Animal Medical
Center of NY in which dogs with spontaneous melanoma were injected with a series of 4 doses of
human tyrosinase DNA vaccine using a needle-free delivery system. Initial results showed a
significant prolongation in the expected survival of a cohort of 9 dogs with advanced melanoma.
Further trials confirmed that vaccination resulted in longer-than-expected survival of dogs in the
minimal residual disease setting and even occasional regressions of large metastases.
Conditional licensure was granted to Merial in 2007 for the use of vaccine in canine melanoma.
Human clinical trials of the mouse tyrosinase vaccine have proceeded with preliminary showing
the ability of xenogeneic DNA immunization to induce CD8+ T cell responses in human
melanoma patients. Vaccination in both humans and dogs has been well tolerated, with transient
injection site reaction being the most common adverse event. This program has demonstrated
the importance of testing novel biologics in a realistic animal model and also the significant
potential for collaboration between human and veterinary cancer investigators.
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PROCESS INTENSIFICATION FOR LARGE SCALE MANUFACTURING ISSUES.
CASE STUDY - INNOVATIVE TECHNOLOGIES APPLIED TO HUMAN INFLUENZA
VACCINES
Jean-Christophe Drugmand, Nicolas Havelange, Naďma Alaoui and Jose Castillo, Artelis
Rue de Ransbeek, 310, Brussels, 1120, Belgium
T: +32 2 264 1862, F: +32 2 264 2600, j.castillo@artelis.be
Elisabeth Maurer, Christian Dietzsch and Thomas Muster, Green Hills Biotechnology
Gersthofer Str. 29-31, A-1180 Vienna, Austria,
T: +43 1 31 99 670, F: +43 1 , 31 96 099, e.maurer@greenhillsbiotech.com,
The demand for influenza vaccines is increasing all over the world. The manufacturing paradigm
of virus production is moving from embryonated eggs to replication on mammalian cell lines. Due
to the market pressure, the targeted production scales lie in the range of 1500L to 5000L.
This presentation focuses on process intensification techniques that Artelis is currently
investigating and developing to face the manufacturing issues related with these challenging
scales.
More specifically, process intensification is implemented by following two axes.
Firstly, the volumetric yield of viral production is increased by 20 to 100 fold compared to
traditional technologies, thanks to the implementation of high cell density fixed bed cell culture.
This patented technology allows staying at small scales for manufacturing, from 25L to 100L.
Secondly, disposable single-use components and systems are implemented for all the unit
operations into the process.
This combined strategy leads to the design of a plastic factory, characterized by a dramatic
reduction of space requirements, investment costs and delivery time. Quantitative evaluations will
be presented.
The advantages of this way to manufacture were assessed in terms of direct and indirect
economical impacts.
Investment costs are reduced by at least 50%, operational costs are decreased by at least 30%,
time-to-market can be decreased by 2 years. Impacts on risks (safety issues, delivery issues) and
pipeline management were also assessed.
Finally, some thoughts will be shared about the issues related to the supply of ready-to-use
culture media and disposables for a plastic factory, as well as the chance for developing countries
to incorporate their own vaccine production thanks to plastic factories.
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MULTIVALENT VACCINES FOR CONTROL AND ERADICATION OF FMD
M. Susana Levy, Biogenesis-Bago S. A.
Ruta Panamericana Km 38.5, Garin, Buenos Aires, B1619IEA, ARGENTINA
T: 00 54 03327 448354, F: 00 54 03327 448347, susana.levy@biogenesisbago.com
Emmanuel G. Régulier, Biogenesis-Bago S. A.
Patricio Massera, Biogenesis-Bago S. A.
Eliana Smitsaart, Biogenesis-Bago S. A.
Ana María Espinoza, Biogenesis-Bago S. A.
Foot and mouth disease (FMD) is a highly infectious viral disease that affects food producing
animals such as cattle, pigs and sheep. The FMD status given by the OIE has a huge financial
impact on economies all over the world. Control and eradication programs rely heavily on the
development of marker vaccines that enable Differentiation of Infected from Vaccinated Animals
(DIVA). In infected animals viral replication leads to the synthesis of antibodies against structural
and non-structural proteins. In animals vaccinated with inactivated virions only antibodies against
structural proteins are synthesized provided the vaccine does not contain residual non-structural
proteins derived from viral replication during the vaccine manufacturing process. Various process
options such as ultrafiltration, precipitation and chromatography have been proposed and
implemented to separate structural from non-structural proteins. A polyethylene glycol
precipitation-based approach provides a robust and simple platform which we have successfully
scaled up to 11000 litres. The process step is suitable for purification of different FMD virus
strains (A Arg 2000, A Arg 2001, A24 Cruzeiro, C3 Indaial, O1 Campos, O Taiwan 97) produced
from cultures of suspension adapted BHK21 cells. Field trials in cattle subjected to multivalent
multiple-dose immunization schemes demonstrated the antigenic purity of the product.
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PROTECTIVE IMMUNE RESPONSES TO PATHOGENIC INFLUENZA USING CONSENSUS
DNA IMMUNOGENS AND CONSTANT CURRENT ELECTROPORATION
Henry Hebel, VGX Pharmaceuticals
2700 Research Forest Drive, Suite 180, The Woodlands, Texas, 77381, USA
T: 281-296-7300, F: 281-296-7333, hhebel@vgxp.com
Dominick Laddy, Pathology & Laboratory Medicine, University of Pennsylvania School of
Medicine
Lauren Hirao, Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine
Amir S. Khan, Ruxandra Draghia-Akli, Niranjan Sardesai, VGX Pharmaceuticals
David B. Weiner, Pathology & Laboratory Medicine, University of Pennsylvania School of
Medicine
The development of novel technologies for immunizing against emerging viral threats presents a
formidable and critical challenge to the bio-pharmaceutical industry. Recently developed
consensus DNA immunogens to pathogenic avian H5N1 influenza have the potential to induce
highly cross-reactive immune responses against different viral subtypes and clades. Using our
proprietary manufacturing process, a single vial multivalent, high concentration vaccine has been
produced in large quantities. Three consensus constructs were produced: pH5HA (a consensus
of 16 clade 1 H5N1 hemagglutinin sequences); pM2eNP (a fusion of the N-terminal domain of the
M2 ion channel with the nucleoprotein antigen, designed from over 40 influenza A sequences);
TM
pN1NA (designed from over 40 N1-neuraminidase sequences). Using the CELLECTRA
constant-current electroporation device to deliver low doses of DNA immunogens, we examined
the induction of protective immune responses against highly pathogenic avian influenza viruses.
Four groups of ferrets were immunized and electroporated with pVax (controls); pH5HA only;
pM2eNP only; or pH5HA, pM2eNP, and pN1NA. Following lethal A/Vietnam/1203/2004 influenza
challenge, 100% survival was observed in each vaccinated group (0% in the control). Maximum
loss of body weight in each group were measured: control animals lost 24.7 ± 1.5% of their body
weight, pH5HA vaccinated animals lost 12.8 ± 5.9% (p = 0.049 vs. control), pM2eNP vaccinated
animals lost 17.4 ± 0.9% (p = 0.003 vs. control) and combination vaccinated animals lost 12.1 ±
2.6% (p = 0.003 vs. control). All vaccinated groups displayed a statistically significant reduction in
viral shedding by day 5 (p < 0.01 comparing control group to vaccinated groups). In the pM2eNP
vaccinated group, with protection based solely on cellular immunity, there was a 90% reduction in
mean viral load. These studies were extended into a primate model of vaccination, demonstrating
the ability of our consensus sequences to induce cellular immune responses in addition to
protective titers of antibody (HI > 1:40) following only two immunizations in rhesus macaques.
These studies demonstrate that the manufacture, formulation and delivery of protective vaccines
for H5N1 influenza can be done efficiently and effectively. Furthermore, delivery of these
consensus DNA immunogens can both elicit protective immune responses and show protection
post-challenge. These studies show promise for this vaccine regimen in human clinical trials.
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INTENSIFYING THE PRODUCTIVITY OF A RECOMBINANT AD35 MANUFACTURING
PROCESS USING THE PER.C6® CELL SUBSTRATE
Alfred Luitjens, Crucell
PO Box 2048, Leiden, 2301 CA, the Netherlands
T: +31 71 519 9245, F: +31 71 519 9800, alfred.luitjens@crucell.com
Crucell and The Aeras Global TB Foundation are collaborating in the development of a
recombinant adenovirus (rAd) based TB vaccine for which Phase I studies have been initiated at
the end of 2006. The vaccine manufacturing process supporting Phase I clinical trials have a
productivity of 700 doses/liter bioreactor volume at a dose of 10E11 virus particles. At this
productivity, at least 150 batches at 1000L scale, or at least 15 batches at 10,000L scale will be
required to provide a minimum of 100-200,000,000 doses to assure an immediate global impact
on disease burden immediately after licensure.
Given the uncertainties attendant to the CAPEX commitment required to develop a facility for a
10,000-liter bioreactor process and the unprecedented need to develop a viral vaccine
manufacturing process at 10,000L scale under BSL 2 conditions, our approach is to focus instead
on an intensification effort on the rAd35 manufacturing process. Accordingly, we have set as an
objective, a 10-20 fold intensification of the Upstream Manufacturing Process to be realized
through increases in both unit and volumetric productivities. The process intensification will be
developed by the use of scale down models that allow for a high throughput analysis of cell
culture and infectivity variables.
This presentation will review our efforts to understand the determinations of unit productivity of
rAd35 replication in PER.C6® cells and to boost volumetric productivities as well through an
understanding and circumvention of the cell density effect which formerly imposed productivity
limits on rAd35 manufacturing processes.
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AFFINITY CHROMATOGRAPHY OF CELL CULTURE DERIVED VACCINIA VIRUS
Michael W. Wolff, Max Planck Institute for Dynamics of Complex Technical Systems
Sandtorstrasse 1, Magdeburg, 39106, Germany
T: +49 391 6110 231, F: +49 391 6110 588, mwolff@mpi-magdeburg.mpg.de
C. Venzke, Otto-von-Guericke Universität, Magdeburg, Germany
S. Post Hansen and R. Djurup, Bavarian Nordic A/S, Kvistgard, Denmark
R. Faber, Sartorius AG, Göttingen, Germany
U. Reichl, Max Planck Institute for Dynamics of Complex Technical Systems and Otto-vonGuericke Universität, Magdeburg, Germany
Smallpox is an acute, highly infectious viral disease unique to humans with a mortality rate
around 25%. It is caused by the Variola virus that belongs to the family of Poxviruses. Smallpox
was responsible for an estimated 300-500 million deaths in the 20th century. Following successful
vaccination campaigns through the 19th and 20th centuries, the World Health Organization
(WHO) certified the eradication of smallpox in 1980. After the eradication, the compulsory
vaccination was abandoned – with the result that about half of the world’s population is not
vaccinated. This represents a potential threat in the case of a deliberate release of Variola virus
as an act of bioterrorism. Consequently, several governments are ordering stock piles of smallpox
vaccines to protect their populations from this remote, but extremely grave threat. MVA-BN® is a
third generation smallpox vaccine based on the Modified Vaccinia Ankara (MVA) virus which
demonstrates superior safety compared to traditional smallpox vaccines based on native Vaccinia
virus (VV) strains. In addition, re-engineered VV represent as a robust vector a platform
technology for vaccine delivery systems as e.g. in the case of HIV, Dengue fever, Japanese
encephalitis and cancer.
Traditionally, VV- and MVA virus based vaccines have been grown in primary chicken embryo
fibroblast cultures and purified either by sucrose cushion or sucrose gradient centrifugation, or by
ultrafiltration. However, a potential shift from primary to continuous cell cultures would impose
stricter requirements regarding the purity level of the vaccines, and a new generation of vaccine
manufacturing processes is needed that include more sophisticated and innovative downstream
techniques for purification.
Here, we report the development of an affinity chromatography of cell culture derived VV after an
initial host cell homogenization and clearance centrifugation. The Vaccinia viral envelope protein
A27L is known to bind to heparin.. Based on this, small scale chromatography experiments with
heparinized polymer beads and cellufine sulfate beads in addition to heparinized cellulose
membranes have been conducted. There we have found that membrane adsorbers are superior
over bead based chromatography media in terms of efficiency and productivity. Subsequent
studies compared ion exchange membrane adsorbers with a heparinized membrane adsorber.
The results indicate that the overall performance of the affinity chromatography in terms of virus
capturing and contaminant removal is better than any of the tested ion exchange membrane
adsorbers. Hence, membrane affinity chromatography represents a valuable choice to capture
VV particles in addition to the general advantages of membrane chromatography.
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TROUBLE-SHOOTING FERMENTATION AND PRIMARY RECOVERY MANUFACTURING
ISSUES IN ORDER TO OPTIMIZE ANTIGEN EXPRESSION USED AS VACCINE
CANDIDATES AGAINST INFECTIOUS DISEASES
Timothy Lee, Sanofi Pasteur
1755 Steeles Avenue West, Willowdale, Ontario, M2R-3T4, Canada
T: 416-667-2426, F: 416-667-2953, tim.lee@sanofipasteur.com
As a process is scaled up, there are several considerations that must be employed both during
fermentation and recovery of the product. Some key empirical parameters such as power/volume
ratios, mass-transfer coefficient (KLa) and mixing time are considered. The KLa value is kept
constant upon scale-up to maintain similar mass-transfer of oxygen at the larger production scale.
One way of keeping the same KLa value as the small scale is to improve the power input by
increasing the number of Rushton impellers or improving mixing by changing the impellers to lowshear Hydrofoil propellers within the large-scale reactor. In E.coli fermentation, it is shown that
oxygen transfer rate at the production scale was improved by increasing the number of flatbladed impellers rather than changing the impeller type. Due to the nature of the bacteria,
shearing was not an issue. Both biomass and antigen concentration increased as a result.
Although the transfer rate is increased using 3 flat-bladed impellers instead of 2 at the production
scale, the overall productivity is still around 72 % in comparison to the yield achieved at the
smaller bench-scale. To improve the productivity at the larger-scale, a lower feeding rate was
adopted at the production scale. By feeding the substrate at a lower feed rate, the culture was
less oxygen starved and had a greater chance of growing and producing product. The strategy
was effective as the product was expressed up to 21 hours of induction using IPTG. Both
hydrodynamic and physiological considerations will promote success of the process upon scaleup.
A number of filtration technologies (micro-filtration, static filtration and ultra-filtration) for
harvesting the culture are discussed. A process consisting of cross-flow micro-filtration,
homogenization and batch clarification using ion-exchange resins has been effective in
recovering the protein. The majority of the cost of the batch adsorption operation is the cost of the
anion-exchange Big beads ($700/ Liter), which is much less than purchasing a filtration unit and
cassettes (approximately $150,000) or a centrifuge ($300,000) for clarification. In addition, as the
beads are cleaned and re-used again, the cost of operating the batch adsorption method is
lowered and the disposable cost can be reduced significantly in comparison to using depth filters
to clarify the antigen. Also, the batch adsorption process can achieve equal to or greater than 90
% protein recovery which is equal to or better than conventional micro-filtration methods. Hence,
the clarification procedure of cell concentration step using a 0.2 um micro-filtration,
homogenization and batch clarification using big beads is an attractive and cost-effective tool in
the clarification of protein antigens for manufacturing.
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TECHNOLOGY TRANSFER AND PROCESS SCALE-UP
Bo Arve, Vaccines R&D, Wyeth Pharmaceuticals
4300 Oak Park Road, Sanford, NC, 27330, USA
T: 919-566-4616, F: 919-708-6111, arveb@wyeth.com
Khurram Sunasara, Krishna Prasad, Daniel Griffin, Steve Doares, Don Durham, Gregory
MacMichael, Vaccines R&D, Wyeth Pharmaceuticals
Kent Murphy, Technical Operations & Product Supply, Wyeth Pharmaceuticals
In a broad sense, Technology Transfer is defined as the transfer of know-how and experience
from an originator to a recipient. In reality it is a highly complex process, which usually plays a
key role in efforts to successfully commercialize new vaccine candidates. Each Technology
Transfer has some unique features. Being able to identify these features, process subtleties and
other key components of the technology transfer can allow a focus on the major risks of the
transfer.
In the development of Prevenar 13, several types of technology transfers were completed.
Selected Case Studies from these transfers and key lessons learned will be presented.

Thursday, June 5

Session 9

PREDICTIVE MODELING IN ROTAVIRUS-LIKE PARTICLES PRODUCTION: IMPROVING
UPSTREAM AND DOWNSTREAM PROCESSING DESIGN
António Roldăo, IBET/ITQB-UNL
Apartado 12, Oeiras, Oeiras, 2781-901, Portugal
T: +351 21 446 94 17, F: +351 21 446 11 61, aroldao@itqb.unl.pt
Tiago Vicente, IBET/ITQB-UNL, Apartado 12, P-2781-901 Oeiras, Portugal
José P. B. Mota ; Rui Oliveira, REQUIMTE, FCT/UNL, P-2829-516 Caparica, Portugal
Manuel J. T. Carrondo, IBET/ITQB-UNL, Apartado 12, P-2781-901 Oeiras, Portugal
Paula M. Alves, IBET/ITQB-UNL, Apartado 12, P-2781-901 Oeiras, Portugal
Optimisation of rotavirus-like particle (RLP) production in insect cells is extremely complex.
Multiplicity of infection (MOI), individual protein production (VP2, VP6 and VP7) and correspondent
assembly into a triple layered particle (RLP) are major challenges for the upstream processing.
Concomitantly, the downstream processing of RLPs faces several setbacks due to the complexity
of the cell cultured bulk imposing a number of purification steps. Thus, strategies to suppress
product-derived contaminants (trimers of VP6 and double layered particles – DLP) negatively
impacting the overall process were designed based on novel mathematical and analytical tools.
Such a rational approach integrating up- and downstream phases will be shown to improve global
yields.
To maximise product synthesis, the starting point consisted in evaluating the effect of MOI on
final VP2 protein synthesis (used as a model for the remaining VPs). A stochastic/structured
mathematical model developed in our group, combining an explicit stochastic infection process
with intracellular mass action kinetics, was used. Final productivities were shown to be a
compromise between high intracellular VP2 templates, obtained at high MOIs, and high infected
cell densities, obtained at low MOIs. In fact, an optimal midterm MOI between 0.01 and 1 pfu.cell1
maximised process productivity. This strategy, further applied to the remaining VPs, will allow
the establishment of optimal operational conditions for maximisation of RLPs production yields
confirming the relevance of mathematical models in process development. Moreover, these
results highlight the relevance of having accurate analyticals for viral stock titers estimation as
MOI variations may compromise process optimisation. Several titration methods were compared.
The techniques that better combined all important variables (accuracy, cost per titration, titration
time and labor intensity) and therefore proved reliable for titer estimation were the TCID50, MTT
and flow cytometric assays with intra-variabilities and costs per titration of 19% and 13.5€,
respectively.
Complementarily to this upstream optimisation, the design of an efficient downstream process
route is equally important. A novel strategy using anion-exchange membrane chromatography
(SartobindTM D membrane adsorber from Sartorius Stedim Biotech) was evaluated as these
permitted high fluxes, rapid processing, little buffer consumption and a validation-free
environment. Screening studies performed to elucidate the effect of the ionic strength and the pH
of the equilibration buffer on the RLP capture efficiency allowed for the definition of best
operational conditions. Moreover, steric mass action formalism was implemented for the
prediction of the adsorption/elution profile of RLPs demonstrating to be an important
mathematical tool for process optimisation. At the end, global downstream processing yields were
improved by 46%.
Mathematical tools were here demonstrated to play a determinant role in optimising RLPs
production. The predictive capacity of the models presented show their utility in both up- and
downstream phases reducing labor time and process costs, and improving yields.
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IMPLEMENTATION OF DISPOSABLE TECHNOLOGY IN VACCINES MANUFACTURING: AN
APPROACH TO EXTRACTABLES/LEACHABLES STUDIES
Dr Hélčne Pora, Pall Life Sciences
3 Rue des Gaudines BP 5253, Saint Germain en Laye, 78175, FRANCE
T: +33608900136, F: +33534529727, helene_pora@europe.pall.com
Dr Weibing Ding, Pall Life Sciences
Disposable technology is being increasingly used within vaccine manufacturing , and the scope of
available technologies makes it applicable to more complex applications. In particular, it is more
and more used in formulation and filling applications . However, more than their stainless steel
counterparts, single-use systems draw concerns about extractables and leachables from organicbased plastics and elastomers from which some compounds may migrate to finished products.
Therefore, it is imperative to develop suitable and convenient methods to study
extractables/leachables from single-use systems in order to address regulatory requirements.
This talk presents a systematic study of extractables from single-use systems into water and
ethanol via novel concepts, practical design, and analytical detection using advanced techniques.
In order to tackle the fairly complex systems, we studied the components first, which included
filters, connectors, and biocontainers, and then examined the whole single-use systems
comprised of filter, tubing, connectors, and biocontainers. This approach greatly simplified the
identification of the extractable compounds from the whole systems. The test design was based
on actual process conditions using a worst-case scenario. The complete extractables results
were obtained using validated analytical methods, including non-volatile residue measurement
and FTIR for qualitative assessment, GC/MS for volatile/semi-volatile compounds, derivatization
GC/MS for organic acids, HPLC/UV, LC/MS and LC/MS/MS for nonvolatile and heat-sensitive
compounds, and ICP/MS for inorganic elemental analysis.
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THE DEVELOPMENT OF AN INACTIVATED JE VACCINE FOR ENDEMIC COUNTRIES
Mahima Datla, Biological E. Limited
18/1&3 Azamabad, Hyderabad, Andhra Pradesh, 500020, India
T: +91 40 3021 4103, F: +91 40 2767 5003, mdatla@biologicale.co.in
INTERCELL AND BIOLOGICAL E: A PROMISING PARTNERSHIP
Intercell AG, a Vienna based fast growing biotechnology company with a focus on the design and
development of novel vaccines had strategically partnered in early 2005 with Biological E. Ltd. an
Indian pharmaceutical drug manufacturing company based at Hyderabad for the development,
manufacture and sales of its Japanese Encephalitis vaccine in Asian endemic market through
technology transfer.
This alliance is anticipated to broaden by combining the strength of Intercell’s Antigen
Identification Program with Biological E’s experience as a leading Asian vaccine manufacturer
and as an active partner in the National Immunization Program of India.
IC51: THE SMART VACCINE
IC51 a new purified inactivated JE SA14-14-2 virus vaccine with a two dose schedule (0, 28 day)
would represent an improvement over the currently licensed three dose JE vaccines. Pivotal
Phase III trials on JE IC51 world over have demonstrated a favorable safety and immunogenicity
profile.
JE PHASE-II CLINICAL TRIAL
Study Description and Objectives
This open label, phase II, single centre study was conducted in India (Bangalore). 60 healthy
children of either sex in the age group of 1 to 3 years were recruited and randomised into 3
treatment groups in a 2:2:1 ratio to receive either 3mcg or 6mcg dose of IC51 or JenceVacTM.
The Primary Objective of the study was to evaluate the immune response to 3 mcg and 6 mcg
dose of IC51 administered in a two dose schedule for optimal dose identification. The Secondary
Objective was to assess safety and reactogenicity of both the IC51 doses and to evaluate their
immunogenicity in comparison with JenceVacTM.
Study Summary
There were no significant differences in immunogenicity between all the three groups. Both IC51
dose groups appeared to have a lower rate of adverse events compared to JenceVacTM.
Study Conclusions
•Both IC51 groups are equally immunogenic and safe compared to JenceVacTM.
•IC51 showed an appealing safety and immunogenicity profile at the full and half adult dose in
children aged 1 to 3 yrs.
•For further development of the IC51 Phase-III pediatric program this data supports the use of the
3 mcg dose in children below 3 years of age.
The encouraging results of this clinical trial have paved way to the Phase-III trial which will follow
shortly. Intercell AG and Biological E. Ltd are excited to accelerate this program and make this
vaccine available to the endemic countries.
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VACCINE DEVELOPMENT FOR DEVELOPING COUNTRIES – REGULATORY APPROACH IN
THE EUROPEAN UNION
Manfred G. Haase, Consultant
Bruder-Grimm-Strasse 14, Langen, Hessen, 63225, Germany
T: 49 6103 928664, F: 49 6102 771251, Manfred_Haase@gmx.de
In 2004, the European Commission made a substantial effort to overcome the numerous still
existing obstacles that hinder the introduction and use of efficacious and safe medicinal products
in developing countries. For four years now, through article 58 of Regulation (EC) 726/2004 the
EU has been in a position to respond to the need to protect public health and to give scientific
assistance via the EMEA to non-EU countries in the context of cooperation with WHO whilst at
the same time allowing rapid access of important new medical products to those countries.
Article 58 entitles the EMEA’s scientific committee CHMP to provide scientific opinions on
products that are intended for use outside the EU. Important aspects of a specific EMEA
guideline on issues regarding the development of the CHMP scientific opinion assessment report
(AR) according to article 58 will be presented. Importantly, the AR contains only conclusions
based on the same quality, safety and efficacy criteria applied to the assessment of vaccines
intended for use in the EU.
Medicines eligible for this procedure are used to treat or prevent diseases of major public interest.
This includes vaccines used in the WHO Expanded Programme on Immunisation or vaccines for
protection against other public health priority infectious diseases largely limited to developing
countries. Research for the development of these vaccines as well as their manufacturing and
performance of clinical trials is primarily conducted by industrialized nations; while the vaccines
themselves have the greatest impact on the social, economic, and political development of
developing countries. This is not always ideal and has sometimes led to obstacles to vaccine
introduction into third world countries. But in recent years we have fortunately been able to
register an increasing number of important vaccine manufacturers in developing countries.
However, the NCAs in many developing countries have still been considered by WHO to be weak
with regards to a state of the art assessment of licensing applications for vaccines. WHO has
been eager in trying to improve the vaccine evaluation capacities of these countries. The EU tries
with the help of the article 58 procedure to circumvent this obstacle.
In 2007, a European manufacturer submitted the first application file to the EMEA under Article 58
for a combined vaccine against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus
influenzae type b, Neisseria meningitides serogroups A and C. The vaccine was to be used
exclusively in markets outside the EU, primarily in Sub-Saharan Africa. Two other applications for
vaccine candidates designed specifically to meet a pressing public health threat in Africa will be
submitted within a short time frame. The outcome of this first application for a heptavalent vaccine
to be administered in the classical EPI will be briefly discussed in this presentation.
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DEVELOPING VACCINES FOR NEGLECTED DISEASES
Douglas Holtzman, Bill & Melinda Gates Foundation
PO Box 23350, Seattle, WA, 98102, USA
T: 206-709-3601, F: 206-709-3170, douglas.holtzman@gatesfoundation.org
Vaccines represent an extremely cost-effective public health intervention. Historically, due to the
lack of market incentives, there has been insufficient investment in vaccines for parasitic diseases
that primarily affect the most impoverished. However recently the R&D landscape has been
changing as governments and foundations increase their investments in product development
through both 'push' and 'pull' mechanisms, and new technologies and increasing biological insight
create opportunities to tackle these challenging diseases. A general overview of the mission of
the Bill & Melinda Gates Foundation and some specific examples of product development
activities the foundation supports will be presented.
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